Curriculum Vitae of - HKU Scholars Hub: Homehub.hku.hk/.../35/?filename=Dr_CS_Chim_Full_20180206.pdf · edicin ospita ng Ko ng (UK), Glas), F FHKCP & On e, l, ng ACP, , FHKA cology

FR

FRCP

RCPath (

SH Ho

P

MB.Ch

P(Londo

(UK), FF

o Profe

De

Q

Un

Curri

Prof Ja

h.B., M.D

on), FRC

FSc (RCP

essor of

epartm

Queen M

niversit

Ho

iculum

of

ames C

D., Ph.D

CP(Edin)

PA), FA

f Haema

ment of M

Mary H

ty of Ho

ong Ko

Vitae

S Chim

., MRCP

), FRCP(

AcadTM,

atology

Medicin

Hospita

ong Ko

ong

m

P (UK),

(Glas), F

FHKCP

y & On

ne,

al,

ong

FACP,

P, FHKA

cology

AM

1

Content (A) Brief Summary p.2-3

(B) General Information p.4-5 Personal details Medical Education & Post-graduate training Qualifications Professional Accreditation Professional Licenses Awards (C) Appointment p.5-11 (i) University of Hong Kong (ii) HK College of Physicians (iii) The Hong Kong Medical Council (iv) Professional Body Appointments (v) Social Services (vi) Hospital Authority (vii) International Appointment or Recognitions (D) Research p.12-50 (i) Publications p.12-48 a) Theses p.12 b) Book Chapter p.12 c) Invited reviews p.12-13 d) Best 10 Publications p.13-14 e) Peer-reviewed articles p.14-39 f) Conference papers p.39-47 g) Local publications p.48 (ii) Research Grants p.49-50(E) Invited Lectures and Advisory Board Meetings p.51-58 (i) International or Regional Lecture (ii) Advisory Board Meetings(F) Teaching p.59-63 (i) Supervision & Examiner of Graduate student (ii) Undergraduate teaching (iii) Mentoring of Junior Staff(G) Administrative Activities p.64-66 (i) University of Hong Kong (ii) Department of Medicine, Queen Mary Hospital

(iii) Professional Body Appointments (iv) Hospital Authority Head Office: Executive Partner - 2001-2002 (H) Knowledge Transfer

(i) Public Lectures (ii ) Hong Kong Society of Myeloma - Patient gathering (iii) Media (iv) Chairperson in International & Local Meetings (v) Guest Advisor & Adjudication - Annual Quiz of Liberal Studies

p.67-69

(I) Editorial Board Members

2

(A) Brief summary

Professor Chim has published >240 publications in international, peer-reviewed journals

including Blood, Journal of Clinical Oncology, Leukemia. Moreover, he is the first and

corresponding author in the majority (>150 publications). Besides, Prof Chim's international

statue is illustrated by the followings. First, Prof Chim was awarded the National Scientific

and Technological Advancement Award in 2009 (國家科學技術進步獎). Secondly, Prof

Chim was awarded the Fellowship of the Royal College of Pathologists (FRCPath)of UK,

Fellowship of the Academy of Translational Medicine Professionals (FAcadTM), European

Society for Translational Medicine (EUSTM) & Global Translational Medicine Consortium

(GTMC) and Founding Fellowship of the Faculty of Science (FFSc), Royal College of

Pathologist of Australia. Thirdly, Prof Chim was editorial board member of >60 journals

including Carcinogenesis, PloS ONE and Bone Marrow Transplantation. Fourthly, Prof

Chim was Advisory Board member of the International Myeloma Working Group,

consultant of the American College of Physicians for Physicians’ Information and Education

Resources (PIER), and Chairman of Education Program, Asia Pacific Hematology

Consortium (APHCON).

Moreover, Prof Chim was invited international abstract reviewer for the annual

meeting of American Society of Hematology (ASH) & European Society for Blood and

Marrow Transplantation (EBMT), external reviewer for major funding agencies from

Leukemia Research, Leukemia & Lymphoma Research, Cancer Research of United Kingdom,

Czech Science Foundation, Association for International Cancer Research (AICR) and

Agency for Science, Technology and Research (A*STAR). Furthermore, he has been

international reviewer for promotion of Associate Professor to tenure FULL Professor

at the National University of Singapore, and external assessor for candidates of

“Distinguished Researcher" and “Professor” to Shanghai Jiao Tong and HuaZhong

3

Universities in addition to frequent invitations to review manuscripts for multiple reputable

international journals including Blood and Leukemia.

Prof Chim has been invited to lecture in post-ASH conference in New York, the Japanese

Society of Medical Oncology (JSMO) in Osaka, European Society for Medical Oncology

(ESMO) in Singapore, Bridging the Gap meeting, organized by the MD Anderson Cancer

Center, Highlight of ASH & International Society of Hematology (ISH). He is also the

Director for training of Haematology & Haematological Oncology, Hong Kong College of

Physicians. Besides, he is the Visiting/Honorary Professor of 7 Medical Universities in

mainland China including the Soozhou University, Shantong University, Peking University,

People’s Liberation Army 301 Hospital (Beijing), Sun Yat-sen University (Guangzhou), and

Tonji Medical School (Wuhan).

Locally, Prof Chim is the Founding & Current President of the Hong Kong Society of

Myeloma, and has been the Chairman of the Hong Kong Society of Haematology.

In addition, Prof Chim has also been awarded competitive RGC & NSFC grants since

2008, and two post-doc fellows. Currently, he is the principal supervisor of 4 PhD students,

and has been twice the external examiner of National University of Singapore. Moreover, his

dedication to teaching is also appreciated by the medical students. Finally, Prof Chim is a

conscientious clinician, and has won substantial appreciation from my patients and relatives.

Amid his busy clinical schedules, he has organized 4 myeloma patient gatherings since Oct,

2015, in which he invited speakers, physiotherapist, dietitian, orthopaedic surgeon,

pharmacist in addition to a pastor to pray for the patients and their families.

Currently, his research focuses on “Epigenetic alterations in Blood Cancers”, and clinical

studies of multiple myeloma.

In summary, Prof Chim is both an experienced physician and clinician scientist,

committed to translating scientific advances to quality patient care. Currently, he is a fellow of

both the Royal Colleges of Physicians and Pathologists.

Name

Addres

Teleph

Medic

1981 –

1980 –

Post-g

1992 -

1997

Qualif

Feb/20

Nov/20

Dec/20

July/20

July/20

Oct/20

May/2

Dec/19

Sep/19

July/19

Mar/19

Feb/19

July/19

Profes

Advan

Haema

Medic

Profes

Hong K

Genera

: Ch

ss : De

Un

hone : 22

cal Educatio

– 1986 Ch

– 1981 Ch

graduate tra

1993 Re

Lo

Ca

fications

016 F

011 F

o

007 F

006 D

004 F

002 D

2002 F

999 F

999 F

995 F

995 F

991 M

986 B

ssional Accr

nced Internal

atology/Hae

al Oncology

ssional Licen

Kong Medic

al Medical C

(Bhim Chor Sa

epartment of

niversity of H

55 4769

on

hinese Unive

hinese Unive

aining

esearch Fello

ondon, UK

ancer Resear

Fellow of the

Founding Fel

f Pathologis

Fellow of the

Doctor of Ph

Fellow of the

Doctor of Me

Fellow of the

Fellow of the

Fellow of the

Fellow of the

Fellow of the

Member of th

Bachelor of M

reditation

l Medicine

ematological

y

nses

cal Council

Council

) Genang, James (

f Medicine, Q

Hong Kong,

ersity of Hon

ersity of Hon

ow, Academ

rch Centre, U

e Academy o

llow, Facult

sts of Austra

e Royal Coll

ilosophy

e American C

edicine, Uni

e Royal Coll

e Royal Coll

e Royal Coll

e Hong Kong

e Hong Kong

he Royal Co

Medicine &

l Oncology

4

neral In(詹楚生)

Queen Mary

Hong Kong

ng Kong F

ng Kong D

mic Departm

University o

of Translatio

ty of Science

alia

lege of Patho

College of P

iversity of H

lege of Phys

lege of Phys

lege of Phys

g Academy

g College of

ollege of Phy

Bachelor of

nformaSex :

Hospital,

Religion

Faculty of M

Department

ent of Haem

of Chicago, U

onal Medicin

e, the Royal

ologist

Physicians

Hong Kong

sicians (Lond

sicians (Glas

sician (Edinb

of Medicine

f Physician

ysician

f Surgery

ation M

n: Christian

Medicine

of Biochem

matology, Ro

USA

ne Professio

College

don)

sgow)

burgh)

e

mistry, Facul

oyal Free Ho

onals FAc

FFS

FRC

Ph.D

FAC

MD

FRC

FRC

FRC

FHK

FHK

MRC

MB

ty of Scienc

ospital,

cadTM

c (RCPA)

CPath (UK)

D. (HK)

CP

(HK)

CP(London)

CP(Glasgow

CP(Edinburg

KAM

KCP

CP(UK)

ChB (CUH

ce

w)

gh)

HK)

5

Awards Croucher Foundation Fellowship Sept/1992 – 1993

National Scientific and Technological Advancement Award, China 2009

國家科學技術進步獎 (二等獎)

Title: 白血病表觀遺傳學基礎及臨床應用研究

(C) Appointments (i) University of Hong Kong:

a) Endowed Professorship, S H Ho Professorship in Haematology and Oncology: 9th December,

2013 – now

b) Senate Membership, 1 April 2017 – 31 March 2020

c) Clinical Professor : July, 2010 - 8th December, 2013

d) Clinical Associate Professor (Senior Lecturer) : 2007 – June, 2010

e) Honorary Associate Professor : 2000 – 2007

f) Honorary Assistant Professor : 1991 – 2000

g) Scientific member, Institutional Review Board of the University of Hong Kong/Hospital

Authority Hong Kong West Cluster, March, 2013 - Feb, 2018

h) Member, Committee of Management for Dr Cheng Yu Tung Fellowships, 1st March 2018 to

29 February, 2020

i) Member, Performance Review and Development (PRD) Appeals Panel, 1st November, 2013-

31st October, 2017

j) Member, Faculty Research Committee, 27th August, 2015-26th August, 2017

k) Departmental representative, Haematology/Immunology System Block Planning Group, 1st,

September 2010-31st, August 2016

l) Member, Faculty Higher Degrees Committee, 1st, August, 2013-31st July, 2016

m) Member of Faculty Computer Committee : 2010 - 2016

n) Member, Committee of Management of the Centre for Genomic Sciences, 24th September,

2013-5th December, 2015

o) Member, Board of Academic Awards, 1st, July, 2013-30th, June, 2015

p) Guest member, Selection Boards for the Sir Edward Youde Memorial Fellowships and

Scholarships 2013-2014, December 2013-January 2014

q) Member, Committee of Management of the Sun Yat Sen Foundation Fund for Academic

Exchanges with China : 2010 – 2013

r) Member, Selection board for the Sir Edward Youde Memorial Scholarship : 2010 - 2011

s) System Coordinator (HI) of Year 2 Coordinating Sub-committee, University of Hong Kong :

2008 – 2010

(ii) Appointments to Local Professional Bodies

(a) HK College of Physicians:

6

a) Haematology & Haematological Oncology : Board Member (1999-2015) & Examiner (

2006-now)

b) Medical Oncology: Board Member (2007- 2010) & Examiner: (2006-now)

c) Board of Critical Care Medicine: Examiner (2007 & 2008)

d) Program Director: Specialty Board in Haematology and Haematological Oncology,

Hong Kong College of Physicians (2010-2015)

e) Research Committee (2013-now)

(b) The Hong Kong Medical Council:

a) Member of the Internship Sub-committee (Since May 2015)

b) Examiner for Licensing Examination, 2007, 2009, 2013

(c) Member, Pharmacy and Poisons Board Hong Kong - Pharmacy and Poisons

Committee, Department of Health (Jan 2016 - Dec 2019)

(d) Member, Health and Medical Research Fund (HMRF) Grant Review Board, organized

by Food and Health Bureau, The Government of HKSAR (Nov, 2013 – Oct, 2017)

(e) Member, Promotion Sub-Committee of the Health Care and Promotion Scheme, Health

Care and Promotion Committee, Food and Health Bureau, The Government of HKSAR

(Sep 2017 - July 2018)

(f) Professional Body Appointments

a) Founding President: Hong Kong Society of Myeloma (Since 2010 - now)

b) Council bearer of the Hong Kong Society of Haematology :

Council member (Apr 2007 – Mar 2008), Chairman (2003-2006), Honorary treasurer

(2000-2003), Honorary secretary (1999-2000), Scientific officer (1998-1999)

c) Council member: Hong Kong Cancer Chemotherapy Society (2002-now)

d) Council member: Federation of Medical Societies of Hong Kong (2003-2014)

e) Director: Foundation of Federation of Medical Societies of Hong Kong (2005-now)

f) Scientific Officer: Hong Kong Society for the Study of Thalassemia (2005-now)

g) Member, Hong Kong Scientist Association (2009-now)

(g) Social Services

a) Member of Cervical Screening Taskforce, Department of Health, Hong Kong (Mar

2002 - Mar 2008)

b) Honorary Advisor: Hong Kong Adult Blood Cancer Group (May 2004 – March

2014, April 2016 – March 2018)

c) Honorary Advisor: Hong Kong Bone Marrow Transplantation Patient Group (July

1997 – now)

d) Advisor, Adjudicator & Guest of Honor of The Medicine Annual Quiz 2012 –

Liberal Studies Cup on Medicine

e) Advisor, Adjudicator & Guest of Honor of The Social Science Annual Quiz 2014/15

– Food Wise Liberal Studies Cup

7

f) Advisor, Adjudicator & Guest of Honor of The Social Science Annual Quiz 2015/16

– Green School

(iii) Hospital Authority

a) Honorary Consultant, Department of Medicine, Queen Mary Hospital: 2007 – now

b) Honorary Oncology Specialist, Department of Medicine & Geriatrics, Kwong Wah Hospital:

2010 – now

c) Scientific Member of IRB since 1 March 2013

d) both a Scientific Member and Phase 1 Panel Member since 1 March 2015

e) Senior Medical Officer 1994 – 2007

f) Medical Officer 1987- 1994

(iv) International Appointment or Recognitions

1. National Scientific and Technological Advancement Award, China 2009

(國家科學技術進步獎 (二等獎)

Title: Epigenetic alterations in acute leukaemia

白血病表觀遺傳學基礎及臨床應用研究

2. Editorial appointments:

a. Editor-in-Chief:

a) Journal of Genetics Study (since Jul 2013)

b) RNA & Disease (since Jan 2017)

b. Senior Editor:

a) American Journal of Translational Research (IF: 2.829)

b) Journal of Gene Therapy Aspects (since Oct 2013)

c. Associate Editor:

a) Clinical Epigenetics (Since Nov 2014) (IF: 4.987)

b) Epigenomics (IF: 4.541) (since 2011)

c) Hematology (since Feb 2013) )(IF: 1.244)

d) Frontiers in Oncology (since Jan 2016 - Nov, 2017)

e) The Journal of Bioscience and Medicine (JBM)

d. Scientific Editor: Translational Oncology (IF: 3.025) (since Mar 2010)

e. Editorial Board Members (of 60 journals, Full list in Annex I)

a) Carcinogenesis (IF: 5.105) (Jan 2009 - Dec 2011)

b) Journal of Hematology & Oncology (IF: 6.350)(since Mar 2012-Sep, 2017)

c) Journal of Translational Medicine (IF: 3.786)(since Nov 2008)

d) Bone Marrow Transplantation (IF: 3.874)(since Feb 2009)

e) PLoS ONE (IF: 2.806)(Since July 2010)

f) Blood Cancer Journal (IF: 6.126)

g) Current Oncology Reports (IF: 2.608)(since Jan 2011)

8

h) International Journal of Oncology (IF: 3.079)(since Feb 2009)

i) Translational Oncology (since Mar 2010) (IF:3.025)

3. Advisory Board Member: International Myeloma Working Group, IMWG

4. Executive Council Member, Asian Myeloma Network

5. Chairman, Education Program, Asia Pacific Hematology Consortium (APHCON),

organized by the MD Anderson Center (since July, 2012)

6. Founding member of International Academy of Clinical Hematology (IACH):

http://clinical-hematology.org/ (since Oct, 2017)

7. Invited member to the Global Committee of the European Society for Blood & Marrow

Transplantation (EBMT) (since Nov, 2017)

8. External Reviewer for Grant Application/Meeting abstracts

a International reviewer, European Society for Blood and Marrow Transplantation

(EBMT), the 44th EBMT Annual Meeting, March 18-21, Lisbon, 2018

Swiss National Science Foundation (SNSF) (Dec 2016): Lifetime social adversity

and biological ageing

b U.S.-Israel Binational Science Foundation (BSF) (Jan 2016): Elucidating the role

and regulation of the AHR/TP73-AS1 signaling axis in glioblastoma [Application #

2015106]

c The Icelandic Research Fund (IRF) (Oct, 2015): Transcriptional enhancers and

long non-coding RNAs in MGUS and multiple myeloma," submitted by Kimberley

Jade Anderson.

d Cancer Research UK (Jan, 2014): Training & Career Development Board - Clinician

Scientist Fellowship. Title: Investigating epigenetic programming and its influence on

tumour cell interactions in the stromal niche as determinants of tumour biology with

multiple myeloma as a model

e Leukaemia & Lymphoma Research (July, 2013): MicroRNA expression in T cells

in haematologic malignancies

f Association for International Cancer Research (AICR)(Dec, 2012): The role of

small noncoding RNAs in T-cell transformation

g Czech Science Foundation (Sep, 2012): The role of tumor suppressors DLC-1/PTEN

in the regulation of cell migration in multiple myeloma

h Research Grant of LEUKAEMIA RESEARCH, United Kingdom

(http://leukaemialymphomaresearch.org.uk), April, 2009: Myeloma Genetics, grant

applied: £1,369,236

i A member of the international Reviewer panel of six (two from Dana Faber Cancer

Institute, Harvard University; one Cornell University and two others from Walter Eliza

Cancer Institute, Australia) for abstracts of the 53rd Annual Meeting of the American

Society of Hematology, San Diego, California, December 10-13, 2011. Abstract Category

9

652-- Myeloma - Pathophysiology and Pre-Clinical Studies, including signal transduction

studies, animal and pre-clinical models as well as preclinical studies of novel emerging

therapies.

j External reviewer for research proposal (006) - Biomarker development, The Agency

for Science, Technology and Research’s (A*STAR), Singapore, Aug, 2011

k Research Grant of Cancer Research, United Kingdom

(http://science.cancerresearchuk.org/research), Sep, 2011: Are DNA methylation

and MMSET histone modifications linked in t(4;14) myeloma?

l Research Fund for the Control of Infectious Disease (RFCID) and the Health and Health

Services Research Fund (HHSRF), Hong Kong SAR Government (March, 2010):

Regulation and function of microRNA-21 in HBV associated hepatocellular carcinoma

9. Fellowship of the Academy of Translational Medicine Professionals (FAcadTM),

accredited by the European Society for Translational Medicine (EUSTM) and the Global

Translational Medicine Consortium (GTMC), Feb 2016

10. Award of the Fellowship of the Royal College of Pathologists, United Kingdom

(FRCPath) by published work and Founding Fellow, Faculty of Science, the Royal

College of Pathologists of Australia FFSc (RCPA)

11. Member, Chinese American Hematologists and Oncologists (CAHON)

12. Member, Clinical Epigenetics Society (CLEPSO)(since 2012)

13. Member, Cancer Epigenetics Society (CES)(since 2016)

14. Member, American Society of Hematology, 2017

15. Member, International Myeloma Society, 2017

16. Consultant of the American College of Physicians:

Physicians’ Information and Education Resources (PIER) (Jan 2008 - Dec 2011)

17. Consultant: Hematological Oncology Division, Guangzhou Anti-cancer Society,

2007-2010 (廣州抗癌協會血液腫瘤專業委員會: 顧問)

18. Visiting/Chair/Honorary/Adjunct Professors

a) Visiting Professor, Peking University People’s Hospital (Nov 2011-)

北京大学人民醫院

b) Visiting Professor: Sun Yat-Sen University, (June 2010 - 2012)

中山大学

c) Chair Professor: Sun Yat-Sen Institute of Hematology (2010-2012)

中山大学血液學研究所

d) Visiting Professor: Chinese PLA Postgraduate Medical School & PLA General

Hospital (Jun 2009-)

北京中國人民解放軍總醫院 (PLA)

e) Visiting Professor: Nanfong Medical University, (Oct 2008- 2011)

南方医科大学

f) Honorary Professor: Tongji Medical University, Wuhan, China (Nov 2008-)

10

武汉华中科技大学

g) Visiting Professor: Capital Medical University, Beijing (Nov 2010-)

首都医科大学

h) Adjunct Professor: Shandong University, (Nov 2011-)

山东大学

i) Visiting Professor: Soochow University, (Mar 2013-)

苏州大学

j) Visiting Professor: West China Hospital, Sichuan University (Jul 2015- 2017)

四川大学华西医院

19. Co-organiser/Chairman of International meetings

a) Co-organizer: Hong Kong Society of Myeloma Scientific Meeting: Multiple

Myeloma Workshop, 30 Jan 2016

b) Chairman: 2nd Asia Pacific B-Cell Malignancies Meeting on 24-25 Oct 2015

c) Member, Program Committee, ACMR 2013, Annual International Conference on

Advances in Cancer Medical Research, Thailand, Nov, 2013

d) Chairman: 4th International Hematologic Malignancies Conference: Bridging

the Gap 2013 (BTG2013) on 22-23 Feb 2013

e) Co-organizer: 3rd International Hematologic Malignancies Conference

'Bridging the Gap 2012 (BTG2012) jointly organized by MD Anderson and

University of Hong Kong on 23-25 Feb 2012

(http://www.asiapacifichematology.org)

20. External Reviewer for:

a) Promotion of Associate Professor, Dr Wee Joo Chng, to Tenure Full Professor in the

Department of Medicine, National University of Singapore (NUS) - June 2014

b) Application for “Distinguished Researcher" to Shanghai Jiao Tong University in

2010, (上海交通大学)

c) Application for “Clinical Professor” of the Huazhong University of Science and

Technology, 2011 (华中科技大学)

21. Invited reviewer to peer-reviewed international journals:

Blood (impact factor: 10.8); Oncogene (impact factor: 7.1); Leukemia (impact factor:

8.6); Oncotarget (IF: 5.168); British Journal of Haematology (impact factor: 4.46);

Bone Marrow Transplantation (impact factor :3.874); International Journal of Cancer

(impact factor: 4.70); European Journal of Cancer; Journal of Cellular and Molecular

Medicine; Journal of Pathology (impact factor: 5.7); Apoptosis; Histopathology;

Journal of Clinical Pathology; Mayo Clinic Proceedings; Leukemia & Lymphoma;

Cancer Chemotherapy & Pharmacology; PLOS One; Nature Reviews Clinical

Oncology; American Journal of Haematology; Acta Haematologica; Hong Kong

Medical Journal; Epigenomics

22. Member of International Scientific Meetings

11

a) International Scientific Committee of 17th International Conference On

Chelation (ICOC) for the Treatment of Thalassaemia, Cancer and other Diseases

related to Metal and Free Radical Imbalance and Toxicity Nov, 2007.

www.icoc-isocam.org

b) Member of the International Scientific Committee of the 18th International

Conference On Chelation (ICOC) for the Treatment of Thalassaemia, Cancer and

other Diseases related to Metal and Free Radical Imbalance and Toxicity, Athens,

Greece, 2008

c) Scientific Committee, 16th Hong Kong International Cancer Congress,

University of Hong Kong, 2009

d) Adjudicator of Young Investigator Award in Biomedicine, HKICC, 2009

12

(D) Research (i) Publications

a) Theses

1. Doctor of Philosophy (2006) : The role of Gene Promoter Methylation in Multiple

Myeloma

2. Doctor of Medicine (2002) : Aberrant Gene Promoter Methylation in Acute

Promyelocytic Leukemia

b) Book Chapter

1. The detection of minimal residual disease in acute leukemia.

L Foroni, L Coyle, MF Cole-Sinclair, JC Yaxley, Chim CS, AV Hoffbrand.

In : Autologous Stem cell Transplantation: Biological and clinical results in

malignancies. Harwood Academic Publisher. Ed. Carella. 1996, p. 89-101.

2. Optimal Therapy for Multiple Myeloma.

JCS Chim, R Liang.

In: ASIA PACIFIC ONCOLOGY & HAEMATOLOGY - VOLUME 1,

Haematological Cancer

c) Invited reviews

1. Chim CS, et al. Gene Hypermethylation in Multiple Myeloma : Lessons from a

Cancer Pathway Approach. Clin Lymphoma Myeloma, 2008 (IF: 2.494)

2. Chim CS, et al. Adverse Prognostic Impact of CDKN2B Hypermethylation in Acute

Promyelocytic Leukemia. Leukemia & Lymphoma; 47(5): 815-825, 2006. (IF:

2.755)

3. Chim CS, et al. Gene promoter hypermethylation in hematologic malignancies.

Hematol Oncol; 20(4):167-76, 2002. (IF:3.118)

4. Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor microRNA

genes: a lesson from miR-34 family. Epigenomics, 2011 (IF: 4.541)

5. Wang LQ, Liang R, Chim CS. Methylation of tumor suppressor microRNAs:

Lessons from lymphoid malignancies. Expert Review of Molecular Diagnostics.

2012 Sep;12(7):755-65. (IF: 3.100)

6. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in

multiple myeloma. Carcinogenesis. 2012 Sep;33(9):1629-38. (IF: 5.105)

7. Yim RLH, Kwong YL, Wong KY, Chim CS. DNA Methylation of Tumor

Suppressive miRNAs in Non-Hodgkin’s Lymphomas. Frontiers in non-coding

RNA, Front Genet. 2012;3:233. doi: 10.3389/fgene.2012.00233. (Review)

13

8. Kwan Yeung WONG, Chor Sang CHIM. DNA methylation of tumor suppressor

protein-coding and non-coding genes in multiple myeloma. Epigenomics, 2015

Sep;7(6):985-1001.

9. Lu Qian Wang, Chor Sang Chim. DNA methylation of tumor suppressor

miRNAs in chronic lymphocytic leukemia. Epigenomics. 7(3):461-73, 2015.

10. Yinlei Bai, Alberto Orfao, Chor Sang Chim. Molecular Detection of Minimal

Residual Disease in Multiple Myeloma. Br J Haematol, 2017, in press.

11. Chim CS, Kumar S, Orlowski R, Cook G, Richardson PG, Gertz M, Giralt S,

Marivi Mateos, Leleu X, Anderson KC. Management of relapsed & refractory

multiple myeloma – novel agents, antibodies, immunotherapies and beyond.

Leukemia, 2017, in press.

d) Best 10 Publications:

1. YL Kwong, WS Kim, ST Lim, SJ Kim, T Tang, E Tse, AYH Leung, CS Chim.

SMILE for natural killer (NK)/T-cell lymphoma: analysis of safety and efficacy from

the Asia Lymphoma Study Group. Blood 2012 Oct 11;120(15):2973-80. (IF: 13.164)

2. KY Wong, Rita LH Yim, CC So, DY Jin, Raymond Liang, CS Chim. Epigenetic

inactivation of the MIR34B/C in multiple myeloma. Blood 2011; 118: 5901-5904.

(IF: 13.164)

3. Kwan-Yeung Wong, Raymond Liang, Chi-Chiu So, Yanting Qi, Dong-Yan Jin,

Joseph F. Costello, Chor-Sang Chim. Epigenetic silencing of miR-203 in

multiple myeloma. Br J Haematol, Sep; 154(5): 569-78. (IF: 5.670)

4. CS Chim, KY Wong, Y Qi, Loong F, WL Lam, LG Wong, Jin DY, Costello JF,

Liang R. Epigenetic inactivation of the miR-34a in hematological malignancies.

Carcinogenesis, 2010, 31(4):745-50. (IF: 5.105)

5. Chim CS, et al. Epigenetic Dysregulation of Wnt Signaling Pathway in Multiple

Myeloma. Leukemia; 21(12): 2527-36, 2007. (IF: 11.702)

6. Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong YL. Aberrant

promoter methylation of the retinoic acid receptor alpha gene in acute

promyelocytic leukemia. Leukemia. 2005 Dec;19(12):2241-6. (IF: 11.702)

7. Chim CS, et al. Nasal NK-cell lymphoma: Long-term treatment outcome and

validity of the IPI Index. Blood 2004, 103: 216-221. (IF: 13.164)

8. Chim CS, et al.SOCS1 and SHP1 Hypermethylation in Multiple Myeloma:

Implications for Epigenetic Activation of the Jak/STAT pathway. Blood 2004; 103:

4630-4635. (IF: 13.164)

9. Chim CS, et al. Long-term outcome of 231 patients with Essential

Thrombocythemia: Prognostic factors for bleeding, thrombosis, myelofibrosis and

leukaemia. JAMA Internal Medicine (previously Archives Internal Medicine), 2005,

165: 2651-2658. (IF:16.538)

14

10. Chim CS, et al. p15 and p16 promotor methylation in acute promyelocytic leukaemia. J Clin Oncol, 19: 2033-2040, 2001. (IF: 24.008)

e) Peer-reviewed articles

- N=243 as of Nov 2017; Authorship: 1st author in 138 (57.8%), 2nd author in 17

(7.2%), 3rd author in 11 (4.6%) & last in 33 (13.9%) and corresponding author in

>150

- H Factor (using Chim CS, Chim JCS, Chim JC or Chim JS): 40 as of Nov, 2017

- Highest Citation: 264

1. Daryl Tan, Jae Hoon Lee, Wenming Chen , Kazuyuki Shimizu, Jian Hou, Kenshi

Suzuki, Weerasak Nawarawong, Shang-Yi Hwang, Chor Sang Chim, Kihyun

Kim, Lalit Kumar, Pamkaj Malhotra, Wee Joo Chng, Brian G.M. Durie for the

Asian Myeloma Network.

Management of Multiple Myeloma in Asia: Resource-stratified Guidelines and

Consensus Statement from the Asian Myeloma Network

Leuk Lym, 2018, in press.

2. Epigenetic silencing of EVL/miR-1 342 in multiple myeloma.

Zhenhai Li, KY Wong, GCF Chan, WJ Chng, CS Chim.

Translational Research, in press. (IF: 4.652)

3. Management of relapsed & refractory multiple myeloma – novel agents,

antibodies, immunotherapies and beyond.

Chim CS, Kumar S, Orlowski R, Cook G, Richardson PG, Gertz M, Giralt S,

Marivi Mateos, Leleu X, Anderson KC.

Leukemia, 2017, in press. (IF: 11.702) (Review)

4. Molecular Detection of Minimal Residual Disease in Multiple Myeloma

Yinlei Bai, Alberto Orfao, Chor Sang Chim

Br J Haematol, 2017, in press. (Review) (IF: 5.67)

5. LDH as a prognostic marker in AL amyloidosis: expected or unexpected?

Chim CS.

Br J Haematol, 2017 Sep; 178(6):833-835. (IF: 5.67)

6. Epigenetic silencing of LPP/miR-28 in multiple myeloma

Li ZH, Wong KW, Chan GCF, CS Chim.

J Clin Pathol, 2017 Aug 3 (IF: 2.687)

7. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic

leukaemia.

TS Chan, R Au-Yeung, CS Chim, SC Wong, YL Kwong.

Annals of Hematology, 2017 May. 96(5):871-872. (IF: 3.083)

8. Hematology oncology practice in the Asia-Pacific APHCON survey results from the

6th international hematologic malignancies conference: bridging the gap 2015,

Beijing, China.

15

Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh

A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S,

Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R,

Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z,

Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S,

Issaragrisil S.

Oncotarget. 2017 Jun 20; 8(25):41620-41630. (IF: 5.168)

9. Review of Newly Registered Oncology Drugs in Hong Kong.

SK Lee, X Chen, TY Cheng, WK Cheung, WY Cheung, SY Choi, HY Chong, LS

Chu, KLK Chung, KH Fung, CY Ho, KYK Ho, RYY Ip, CX Ko, KT Kong, HS

Kwan, CLY Ewing, VKC Wong, CS Chim.

HKPJ 23 (3), p.86-97, 2016

10. High applicability of ASO-RQPCR for detection of minimal residual disease in

multiple myeloma by entirely patient-specific primers/probes.

Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung, CS Chim.

Journal of Hematology & Oncology, 2016 Oct 11; 9(1):107. (IF: 6.350)

11. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in

chronic lymphocytic leukemia.

Lu Qian Wang, Kwan Yeung Wong, Zhen Hai Li, Chor Sang Chim.

Oncotarget, 2016 Dec 13; 7(50):82400-82410. (IF: 5.168)

12. Asia Pacific Hematology Consortium report on approach to multiple myeloma.

Survey Results from the 6th International Hematologic Malignancies Conference:

Bridging The Gap 2015, Beijing, China.

Jin Lu, Jian Hou, Kaiyan Liu, Simrit Parmar, Adolfo de la Fuente Burguera, Borje

Andersson, Chenhua Yan, Daobin Zhou, Daryl Tan, David Ritchie, Deipei Wu,

Elizabeth Shpall, Ginna Laport, Jianyong Li, Jiong Hu, Lian Sheng Zhang, Michael

Wang, Malhotra Pankaj, Jiang Qian, Yazhen Qin, Raymond Wong, Richard

Champlin, Surapol Issaragrisil, Swaminathan Iyer, Vikram Mathews, Yu Wang,

Yu Hu, Zhijian Xiao, Zonghong Shao, Rafael David Rosengarten, Jon Steuernagle,

Xiao Jun Huang, Robert Z. Orlowski, Chor Sang Chim.

Leuk Lymphoma, 2016 Jun; 91(6): 575-80. (IF: 2.755)

13. Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional

Retrospective Study of 172 Patients.

A Jurczyszyn, J Czepiel, A Gozzetti, A Cerase, V Hungria, E Crusoe, AL Silva, R

Vij, MA Fiala, J Caers, L Rasche, AK Nooka, S Lonial, DH Vesole, S Philip, S

Gangatharan, A Druzd-Sitek, J Walewski, A Corso, F Cocito, M-C M Vekemans, E

Atilla, M Beksac, X Leleu , J Davila, A Badros, R Niesvizky, E Aneja, N Abildgaard,

E Kastritis, D Fantl, N Schutz, T Pika, A Butrym, M Olszewska-Szopa, L

Usnarska-Zubkiewicz, N Grząśko, S Usmani, H Nahi, CS Chim, C Shustik, K Mądry,

16

S Lentzsch, A Świderska, G Helbig, R Guzicka-Kazimierczak, N Lendvain, A

Waage, KT Andersen, H Murakami, S Zweegman, AB Skotnicki, and JJ Castillo. Am

J Hematol. 2016 Jun; 91(6):575-80. (IF: 5.275)

14. Management of Relapsed Multiple Myeloma: Recommendations of the International

Myeloma Working Group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu

X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ,

Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin

J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E,

McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC,

Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG.

Leukemia. 2016 May; 30(5):1005-17. (IF: 11.702) (Review)

15. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic

lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT

signaling pathways.

Lu Qian Wang, Kwan Yeung Wong, Anders Rosèn and Chor Sang Chim

Oncotarget. 2015 Dec 29; 6(42):44422-36. (IF:5.168)

16. Pharmacokinetics and safety of the proteasome inhibitor Ixazomib plus

lenalidomide-dexamethasone in Asian patients with relapsed/refractory multiple

myeloma.

Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond

SM Wong, Chor Sang Chim, Michael J. Hanley, Huyuan Yang, Karthik

Venkatakrishnan, Ai-Min Hui, Dixie-Lee Esseltine, Wee Joo Chng.

J Hematol Oncol, 2015 Sep 4;8:103. (IF: 6.350)

17. Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma

Wong KY, Li Z, Zhang X, Leung GKK, Chan GCF, Chim CS.

Molecular Cancer, 2015 Sep 26;14(1):175. (IF:6.204)

18. DNA methylation of tumor suppressor protein-coding and non-coding genes in

multiple myeloma.

Kwan Yeung WONG, Chor Sang CHIM

Epigenomics, 2015 Sep;7(6):985-1001. (IF:4.541) (Review)

19. DNA methylation of tumor suppressor miRNAs in chronic lymphocytic leukemia

Lu Qian Wang, Chor Sang Chim

Epigenomics. 7(3):461-73, 2015. (IF:4.541) (Review)

20. Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.

Qi Zhang, Lu Qian Wang, Kwan Yeung Wong, Zhen Yu Li, Chor Sang Chim.

J Clin Pathol, 2015; 68(7):557-61. (IF:2.687)

17

21. The Role of Magnetic Resonance Imaging in the Management of Patients with

Multiple Myeloma: a Consensus Statement on behalf of the International Myeloma

Working Group

Meletios Athanasios Dimopoulos, Jens Hillengass, Saad Usmani, Elena Zamagni,

Suzanne Lentzsch, Faith Davies, Noopur Raje, Orhan Sezer, Sonja Zweegman, Jatin

Shah, Ashraf Badros, Kazuyuki Shimizu, Philippe Moreau, Chor-Sang Chim, Juan

Jose Lahuerta, Jian Hou, Artur Jurczyszyn, Hartmut Goldschmidt, Pieter Sonneveld,

Antonio Palumbo, Heinz Ludwig, Michele Cavo, Bart Barlogie, Kenneth C

Anderson, G David Roodman, S. Vincent Rajkumar, Brian Durie, and Evangelos

Terpos

J Clin Oncol, 2015 Feb 20;33(6):657-64. (IF: 24.008)

22. Methylation of miR-155-3p in mantle cell and other non-Hodgkin's lymphoma

Rita LH YIM, Kwan Yeung WONG, Yok Lam KWONG, Florence LOONG,

Chung Ying LEUNG, Raymond CHU, William W LAM, Pak Kwan HUI,

Raymond LAI, Chor Sang CHIM

Oncotarget, 2014 Oct 30;5(20):9770-82 (IF: : 5.168)

23. LDH is an adverse prognostic factor independent of ISS in transplant-eligible

myeloma patients receiving bortezomib-based induction regimens.

CS Chim, Joycelyn Sim, Sidney Tam, Eric Tse, AKW Lie, YL Kwong.

European Journal Hematology, 2015 Apr;94(4):330-5. (IF: 2.653)

24. Bortezomib/bendamustine/dexamethasone induced good partial response in refractory

relapse post-ASCT with constitutive RAS activation due to V600E BRAF mutation

Chor Sang CHIM, Kwan Yeung WONG

Bone Marrow Transplantation, 49(12):1545-7, 2014 (IF: 3.874)

25. RANKL Expression in Myeloma Cells is regulated by a network involving RANKL

promoter methylation, DNMT1, microRNA and TNF in the Microenvironment.

Lingqing Yuan, Godfrey Chi Fung Chan, Kwong Lam Fung, CS Chim.

BBA - Molecular Cell Research, 2014 Sep;1843(9):1834-8. (IF: 4.521)

26. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult

ALL: myeloablative, non-myeloablative and beyond

Hwang YY, Mohty M, Chim CS

Hematology, 20(2):61-71, 2015. (IF: 1.244)

27. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.

Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki

K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS,

Nawarawong W, Siritanaratkul N, Durie BG.

Am J Hematol. 2014 Jul;89(7):751-6. (IF: 5.275)

28. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute

promyelocytic leukemia.

18

Ho Yin Ng, Thomas S Wan, Chi Chiu So, Chor Sang Chim

Journal of Clinical Pathology. 2014 Jul;67(7):626-31. (IF: 2.687)

29. Epigenetic inactivation of miR-34b/c in addition to miR-34a and DAPK1 in chronic

lymphocytic leukemia.

Lu Qian Wang, Yok Lam Kwong, Kit Fai Wong, Chi Shan Bonnie Kho, Dong Yan

Jin, Eric Tse, Anders Rosèn and Chor Sang Chim

J Transl Med. 2014 Feb 22;12(1):52. (IF:3.786)

30. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia

- implications on constitutive activation of NFkappaB pathway.

Wang LQ, Kwong YL, Kho CS, Wong KF, Wong KY, Ferracin M, Calin GA, Chim

CS.

Mol Cancer. 2013 Dec 27;12:173. (IF: 6.204)

31. Establishment of a Chinese human multiple myeloma cell line: MMLAL.

Kwan Yeung WONG, Thomas SK Wan, Chi Chiu So, Chor Sang Chim.

Cancer Cell Int. 2013 Dec 12;13(1):122. (IF: 2.740)

32. Unsustained CR of less than 24 months after autologous stem cell transplantation

predicts aggressive myeloma with short survival.

CS Chim, Herman Liu, AKW Lie, EYT Chan, Sandy Ho, Michael Wong and YL

Kwong for the Hong Kong Society of Myeloma

Hematol Oncol, 2014 Jan 29. (IF: 3.118)

33. 11C-Acetate for Metabolic Characterization of Multiple Myeloma – A Comparative

PET/CT Study with 18F-Fluorodeoxyglucose PET/CT

Chi-lai Ho, S Chen, YL Leung, T Cheng, Ka-nin Wong, SK Cheung, R Liang, C S

Chim

Journal of Nuclear Medicine, 2014 May;55(5):749-52 (IF: 6.646)

34. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report

from the international myeloma working group (IMWG).

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R,

Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC,

Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R,

McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J,

Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H,

Durie BG, San Miguel JF

Leukemia. 2014 Mar;28(3):525-42. (IF: 11.702)

35. Management of multiple myeloma in Asia: resource-stratified guidelines.

Tan D, Chng WJ, Chou T, Nawarawong W, Hwang SY, Chim CS, Chen W, Durie

BG, Lee JH

Lancet Oncol. 2013 Nov;14(12):e571-81. (IF: 33.900)

19

36. Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in

Philadelphia-negative myeloproliferative neoplasm.

Zhang MY, Fung TK, Chen FY, Chim CS

J Cell Mol Med. 2013 Oct 16. doi: 10.1111/jcmm.12103. [Epub ahead of print] (IF:

4.499)

37. IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi

N, Palumbo A, San Miguel J, Sonneveld P, Usmani S, Durie BG, Avet-Loiseau H.

Leukemia. 2014 Mar;28(3):525-42. (IF: 11.702)

38. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated

with the SMILE protocol: diagnostic and prognostic significance.

Kwong YL, Pang AW, Leung AY, Chim CS, Tse E.

Leukemia. 2013 Jul 11. (IF: 11.702)

39. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk

hospitalized hematologic patients.

Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, Khong PL, Tse E, Leung AY,

Chim CS, Lie AK, Kwong YL.

Ann Hematol. 2014 Mar;93(3):493-8. (IF: 3.083)

40. An extraordinary survival of >20 years in a myeloma patient with an unusual

combination of t(14;16) and hyperdiploidy.

Chim CS, ESK Ma

Oncology letter, 2013 Dec;6(6):1663-1664. (IF: 1.390)

41. Relapses of acute leukemia after allogeneic hematopoietic stem cell transplantation:

second transplantation with reduced intensity conditioning from the original donor

Leung AYH, Tse E, Hwang YY, Chan TSC, Gill H, Chim CS, Lie AKW, Kwong

YL.

Am J Hematol, 2013 Jun;88(6):485-91. (IF: 5.275)

42. Epigenetic inactivation of the MIR129-2 in hematological malignancies.

Wong KY, Yim RLH, Kwong YL, Leung CY, Hui PK, Cheung F, Liang R, Jin DY,

Chim CS.

J Hematol Oncol, 2013: 6, 16. (IF: 6.350)

43. Plasma cell leukemia: consensus statement on diagnostic requirements, response

criteria and treatment recommendations by the International Myeloma Working

Group.

Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek

R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R,

Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo

M, Leleu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH,

20

Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J,

Orlowski RZ, Shah JJ.

Leukemia. 2013 Apr;27(4):780-91. (IF: 11.702)

44. Anti-fungal drug usage in hematologic patients during a 4-year period in an Asian

university teaching hospital.

Chan TS, Hwang YY, Gill H, Cheung WW, Tse E, Leung AY, Chim CS, Lie AK,

Kwong YL.

Intern Med J. 2013 May;43(5):541-6 (IF: 1.902)

45. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of

chronic myeloid leukemia.

Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y,

Chim CS, Zheng X, Yu L.

Oncogene. 2014 Jan 2;33(1):44-54. (IF: 7.519)

46. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to

lenalidomide.

Chim CS, Choi PT, Lee WK.

Annals Hematol. 2013 Jun;92(6):855-7. (IF: 3.083)

47. Oligoclonal reconstitution masquerading as myeloma relapse.

Chim CS, Chan YET.

Ann Hematol. 2013 Jun;92(6):847-8. (IF: 3.083)

48. DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin’s Lymphomas.

Yim RLH, Kwong YL, Wong KY, Chim CS. (Invited review)

Frontiers Genet. 2012 Nov 8;3:233.

49. SMILE for natural killer (NK)/T-cell lymphoma: analysis of safety and efficacy from

the Asia Lymphoma Study Group.

YL Kwong, WS Kim, ST Lim, SJ Kim, T Tang, E Tse, AYH Leung, CS Chim.

Blood. 2012 Oct 11;120(15):2973-80. (IF: 13.164)

50. Positron emission tomography in the diagnosis of disseminated pyomyositis due to

PVL-negative methicillin-resistant Staphylococcus aureus.

Gill H, Kwok H, Mak HK, Chim CS, Kwong YL.

QJM. 2013 May;106(5):485-6. (IF: 3.131)

51. DNA methylation of microRNA genes in multiple myeloma.

Wong KY, Huang X, Chim CS. (Invited review)

Carcinogenesis. 2012 Sep;33(9):1629-38. (IF: 5.105)

52. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese

myeloma patients receiving bortezomib-based induction regimens including the

staged approach, PAD or VTD.

Chim CS, Lie AKW, Chan YET, et al. for the Hong Kong Society of Myeloma.

Journal of Hematology and Oncology. 2012 Jun 8;5(1):28. (IF: 6.350)

21

53. Methylation of tumor suppressor microRNAs: Lessons from lymphoid malignancies.

Wang LQ, Liang R, Chim CS. (Invited review)

Expert Review of Molecular Diagnostics. 2012 Sep;12(7):755-65. (IF: 3.100)

54. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients:

late onset and favorable response to treatment. Chan TS, Hwang YY, Gill H, Au WY,

Leung AY, Tse E, Chim CS, Loong F, Kwong YL.

Clin Transplant. 2012 Sep-Oct;26(5):679-83. (IF: 1.865)

55. Role of PCDH10 and its hypermethylation in human gastric cancer.

Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L.

Biochim Biophys Acta. 2011 Dec 20. (IF: 4.521)

56. Methylation of miR-34a, miR-34b/c, miR-124a and miR-203 in Ph-negative

myeloproliferative neoplasms.

Chim CS, Wan TS, Wong KY, Fung TK, Drexter HG, Wong KF.

J Transl Med, 2011 Nov 14;9(1):197. (IF: 3.786)

57. Epigenetic inactivation of the MIR34B/C in multiple myelo.

KY Wong, Rita LH Yim, CC So, DY Jin, Raymond Liang, CS Chim

Blood. 2011; 118: 5901-5904. (IF: 13.164)

58. MAGIC (MyelomA Genetics International Consortium).

Morgan G; Johnsen HE; Goldschmidt H; Palumbo A; Cavo M; Sonneveld P; San

Miguel JF; Chim CS; Browne PV; Einsele H; Waage A; Hajek R; Ludwig H;

Turesson I; Spencer A; Hemminki K.

Leuk Lymphoma. 2012 May;53(5):796-800. (IF: 2.755)

59. Atypical Burkitt’s lymphoma transforming from follicular lymphoma.

Hwang YY, Loong F, Chung LP, Chim CS

Diagnostic Pathol. 2011 Jul 8;6:63. (IF: 2.087)

60. Epigenetic silencing of miR-203 in multiple myeloma.

Kwan-Yeung Wong, Raymond Liang, Chi-Chiu So, Yanting Qi, Dong-Yan Jin,

Joseph F. Costello, Chor-Sang Chim.

Br J Haematol. Sep; 154(5): 569-78. (IF: 5.670)

61. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated

apoptosis via post-translational modification.

Bing Zou, C.S. Chim, Roberta Pang , Hui Zeng, Yun Dai, Rongxin Zhang, Colin S.C.

Lam, Victoria P.Y. Tan, Ivan F.N. Hung, Huiyao Lan, Benjamin C.Y. Wong.

Mol Carcinog. 2012 May;51(5):422-32. (IF: 4.185)

62. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment

results.

Gill H, Chim CS, Au WY, Loong F, Tse E, Leung AY, Kwong YL.

Ann Hematol. 2011 Apr 8. (IF: 3.083)

63. Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies.

22

KY Wong, CC So, F Loong, LP Chung, WWL Lam, R Liang, DY Jin, CS Chim.

PloS ONE. 2011 Apr 22;6(4):e19027. (IF: 2.806)

64. Epigenetic inactivation of the miR-203 in haematological malignancies.

Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L.

J Cell Mol Med, 2011 Dec;15(12):2760-7. (IF: 4.499)

65. Factors affecting mesenchymal stromal cells yield from bone marrow aspiration.

Li J1, Wong WH, Chan S, Chim JCS, Cheung KM, Lee TL, Au WY, Ha SY, Lie

AK, Lau YL, Liang RH, Chan GC.

Chin J Cancer Res. 2011 Mar;23(1):43-8. (IF: 3.000)

66. Updated survivals and prognostic factor analysis in myeloma treated by a staged

approach use of bortezomib/thalidlomide/dexamethasone in transplant eligible

patients.

Chim CS.

J Transl Med. 2010; 8: 124. (IF: 3.786)

67. DNA methylation of tumor suppressor microRNA genes: a lesson from miR-34

family.

Wong KY, Yu L, Chim CS.

Epigenomics. February 2011; 3(1): 83-92. (IF: 4.541)

68. Multiple Myeloma Presenting as Interstitial Lung Disease.

Ma ATW, Lo R, Cheng S, Chim CS.

J Clin Oncol. 2011 Feb 20;29(6):e143-4. (IF: 24.008)

69. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative

neoplasms.

Chim CS, Wan TS, Fung TK, Wong KF.

J Clin Pathol.2010; 63(10):942-6. (IF: 2.687)

70. A staged approach with vincristine, adriamycin and dexamethasone followed by

bortezomib, thalidomide and dexamethasone before autologous hematopoietic stem

cell transplantation in the treatment of newly diagnosed multiple myeloma.

Chim CS, Lie AKW, Chan EYT1, Leung YY1, Cheung SCW2, Chan SYT, Liang R,

Kwong YL.

Annals Hematol. 2010 Oct; 89(10): 1019-27. (IF: 3.083)

71. CD44 activation in mature B-cell malignancies by a novel recurrent IGH

translocation.

Hu XT, Chen YW Chen, Liang CT, Au WY, Wong KY, Wan SK, Wong LY, Shen L,

Chan KK, Guo T, Chu KM, Tao Q, Chim CS, Loong F, Choi WL, Lu L, So CC,

Chan LC, Kwong YL, Liang R, Srivastava1 G.

Blood. 2010; 115(12):2458-61. (IF: 13.164)

72. Epigenetic inactivation of the miR-34a in hematological malignancies.

CS Chim, KY Wong, Y Qi, Loong F, WL Lam, LG Wong, Jin DY, Costello JF,

23

Liang R.

Carcinogenesis. 2010; 31(4):745-50. (IF: 5.105)

73. Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble

Wnt inhibitors in Essential Thrombocythemia.

Chim CS, Fung TK, Liang R.

J Clin Pathol. 2010; Jun; 63(6): 518-21. (IF: 2.687)

74. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in

essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.

Chim CS, Sim JP, Chan CC, Kho BC, Chan JC, Wong LG, Law M, Liang R, Kwong

YL.

Hematology. 2010 Aug; 15(4): 187-92. (IF: 1.244)

75. International Myeloma Working Group guidelines for the management of multiple

myeloma patients ineligible for standard high-dose chemotherapy with autologous

stem cell transplantation.

Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R,

Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S,

Anderson KC, Richardson PG, Cavo M,Davies F, Blad J, Einsele H, Dimopoulos

MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro

M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie

BG, Lonial S.

Leukemia, 2009 Oct;23(10):1716-30. (IF: 11.702; international myeloma working

group advisory board member)

76. Restoration of Chemosensitivity by Bortezomib: Implication for Refractory

Myeloma.

Chim CS, Hwang YY, Pang C, Shek TW.

Nat Rev Clin Oncol. 2009 Apr; 6(4):237-40. (IF: 20.693)

77. Gene Hypermethylation in Multiple Myeloma : Lessons from a Cancer Pathway

Approach.

Chim CS, Kwong YL, Liang R.

Clinical Lymphoma Myeloma. 2008 Dec;8(6):331-9. (IF: 2.494)

78. Epigenetic Dysregulation of the Wnt Signaling Pathway in Chronic Lymphocytic

Leukemia (CLL)

Chim CS, Pang R, Liang R

J Clin Pathol. 2008 Nov;61(11):1214-9. (IF: 2.687)

79. Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis

pathway in acute leukaemias.

Chim CS, Chan WWL, Kwong YL.

J Clin Pathol. 2008 Jul;61(7):844-7. (IF: 2.687)

24

80. Rapid complete remission in multiple myeloma with Bortezomib / thalidomide /

dexamethasone combination therapy following development of tumor lysis syndrome.

Chim CS.

Cancer Chemotherapy and Pharmacology, 2008 Jun; 62(1):181-2. (IF: 3.131)

81. Multiple myeloma with testicular involvement

Chim CS, Hwang YY, Shek TW.

J Clin Oncol; 2008 Mar 20; 26(9):1558-9 (IF: 24.008)

82. Pulmonary interstitial amyloidosis complicating multiple myeloma

Chim CS, Wong M, Fan YS

J Clin Oncol, 2008 Jan 20; 26(3):504-6. (IF: 24.008)

83. Breast and pelvic masses in a myeloma patient.

Hwang YY, Chim CS, Chan G, Loong F, Yau T.

Ann Hematol. 87(12):1027-9, 2008. (IF: 3.083)

84. Frequent epigenetic inactivation of the Rb1 in addition to p15 and p16 in mantle cell

and follicular lymphoma.

Chim CS, Wong KY, Loong F, WW Lam, Srivastava G.

Human Pathol. 2007 Dec;38(12):1849-57. (IF: 3.014)

85. Epigenetic Dysregulation of Wnt Signaling Pathway in Multiple Myeloma.

Chim CS, R Pang, TK Fung , CL Choi , R Liang.

Leukemia. 2007 Dec;21(12):2527-36. (IF: 11.702)

86. Long-term results of allogeneic bone marrow transplantation for 108 adult patients

with acute lymphoblastic leukemia: favorable outcome with BMT at first remission

and HLA-matched unrelated donor.

Chim CS, Lie AKW, Liang R, Au WY, Kwong YL.

Bone Marrow Transplantation, 2007 Aug;40(4):339-47. (IF: 3.874)

87. Fine needle aspiration cytology of folliclar dendritic cell sarcoma: a report of two

cases and review of literature.

Fan YS, Ng WK, Chan A, Chan GSW, Tsang J, Chim CS, Ip P.

Acta Cytologica, 2007, Jul-Aug; 51(4):642-7. (IF: 1.562)

88. Epigenetic dysregulation of the death-associated protein kinase / p14 / HDM2 / p53

/Apaf-1 apoptosis pathway in multiple myeloma.

Chim CS, Liang R, Fung TK, Choi CL, Kwong YL.

J Clin Pathol. 2007 Jun; 60(6): 664-9. (IF: 2.687)

89. Aberrant gene methylation implicated in the progression of monoclonal gammopathy

of undetermined significance to multiple myeloma.

Chim CS, Liang R, Leung MH, Kwong YL.

J Clin Pathol. 2007 Jan; 60(1):104-6. (IF: 2.687)

90. Pathological bone fracture in non-Hodgkin's lymphoma.

Chim CS, Yiu CP, Shek TW.

25

J Clin Oncol, 25(21):3175-6, 2007. (IF: 24.008)

91. Use of Fludarabine-Containing Chemotherapeutic Regimen Results in Durable

Complete Remission of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

Chim CS, Loong F, Ng WK, Kwong YL.

Am J Clin Dermatol, 9 (6): 396-398, 2008. (IF: 2.755)

92. Deafness associated with the use of Bortezomib in Multiple Myeloma

Chim CS, Wong LG.

Acta Oncologica, 2007 Aug 29:1-2 (IF: 3.156)

93. Correlation between the single-site CpG methylation and expression silencing of the

XAF1 gene in human gastric and colon cancers.

Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J, He H, Jiang

SH, Sun YW, Yu LF, Yuen ST, Kung HF, Wong BC.

Gastroenterology. 2006 Dec;131(6):1835-43. (IF: 18.392)

94. Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic

leukemia.

Chim CS, Fung TK, Wong KF, Lau JS, Liang R.

Leuk Res. 2006 Sep; 30(9):1135-9. (IF: 2.501)

95. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in

chronic lymphocytic leukaemia in Chinese patients.

Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R.

J Clin Pathol. 2006 Sep; 59(9): 921-6. (IF: 2.687)

96. Aberrant gene promoter methylation marking disease progression in multiple

myeloma.

Chim CS, Liang R, Leung MH, Yip SF, Kwong YL.

Leukemia. 2006 Jun; 20(6): 1190-2. (IF: 11.702)

97. Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia:

an independent poor prognostic factor.

Chim CS, Chan WW, Pang A, Kwong YL.

Leukemia. 2006 May; 20(5): 907-9. (IF: 11.702)

98. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic

leukemia.

Chim CS, Kwong YL.

Leuk Lymphoma. 2006 May; 47(5):815-25. Review. (IF: 2.755)

99. CDKN2B methylation is an independent poor prognostic factor in newly diagnosed

acute promyelocytic leukemia.

Chim CS, Lau JS, Wong KF, Kwong YL.

Leukemia. 2006 Jan;20(1):149-51. (IF: 11.072)

100. Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic

lymphocytic leukemia.

26

Chim CS, Fung TK, Wong KF, Lau JS, Liang R.

J Hum Genet. 2006; 51(9):832-8. (IF: 2.471)

101. Primary large B-cell lymphoma of the ampulla of Vater.

Chim CS, Yuen WK, Loong FL, Hu WH, Ooi GC.

Haematologica, 2006; 91(3): ECR06. (IF: 7.702)

102. EBV-associated synovial lymphoma in a chronically inflamed joint in rheumatoid

arthritis receiving prolonged methotrexate treatment.

Chim CS, Pang YY, Ooi GC, Shek TW.

Haematologica, 2006; 91(8 Suppl): ECR31. (IF: 7.702)

103. Radiologic manifestations of primary solitary extramedullary and multiple solitary

plasmacytomas.

Ooi GC, Chim JCS, Au WY, Khong PL.

AJR Am J Roentgenol 2006; 186(3): 821-7. (IF: 2.778)

104. Use of the oral chelator deferiprone in the treatment of iron overload in patients with

Hb H disease.

Chan JCW, Chim CS, Ooi GC, Cheung B, Liang R, Chan TK, Chan V.

Br J Haematol; 133(2): 198-205, 2006 (IF: 5.670)

105. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute

promyelocytic leukemia.

Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong YL.

Leukemia. 2005 Dec;19(12):2241-6. (IF: 11.702)

106. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.

Chim CS, Wong AS, Kwong YL.

Am J Hematol. 2005 Dec; 80(4): 282-7. (IF: 5.275)

107. Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute

promyelocytic leukaemia treated with arsenic trioxide.

Au WY, Fung AT, Ma ES, Chan CH, Wong KF, Chim CS, Liang RH, Kwong YL.

Br J Haematol. 2005 Dec; 131(5): 632-5. (IF:5.670)

108. Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase

inhibitors in multiple myeloma.

Chim CS, Liang R, Fung TK, Kwong YL.

Leukemia. 2005 Dec; 19(12): 2352-5. (IF: 11.702)

109. Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia treated with

fludarabine : case report and review of literature.

Leung YH, Tsang W, Chim CS.

Am J Haematol. 2005 Jul;79(3):246-7. (IF: 5.275)

110. A long-term follow-up study on hepatitis B surface antigen positive patients

undergoing allogeneic hematopoietic stem cell transplantation.

27

Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS,

Kwong YL, Liang R, Lau GK.

Blood. 2005 Jul 15;106(2):464-9. 2005 (IF: 13.164)

111. Absence of ATM hypermethylation in mantle cell and follicular lymphoma.

Chim CS, Wong KY, Loong F, Srivastava G.

Leukemia. 2005 May; 19(5): 880-2. (IF: 11.702)

(IF: 8.634; citation: 7; contribution: 90%; 1st and corresponding author)

112. Der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior

treatment.

Chim CS, Ma SK.

Hematol Oncol. 2005; 23(2): 57-60. (IF: 3.118)

113. Clinicopathologic features and treatment outcome of mature T-cell and natural

killer-cell lymphomas diagnosed according to the World Health Organization

classification scheme: a single center experience of 10 years.

Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E,

Yau CC, Liang R, Kwong YL.

Ann Oncol 2005; 16: 206-14. (IF: 11.855)

114. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the

role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in

detecting occult bone marrow involvement.

Chim CS, Ma SK Loong F, Kwong YL.

J Clin Pathol; 58(4): 443-5, 2005. (IF: 2.687)

115. Primary Anaplastic Large Cell Lymphoma of the Pancreas.

Chim CS, Ho J, Ooi GC, Choy C, Liang R.

Leukemia & Lymphoma; 46(3): 457-9.2005. (IF: 2.755)

116. Primary gastrointestinal lymphoma of the Colon.

Chim CS, Shek TW.

Haematologica Nov; 90 Suppl: EIM01, 2005. (IF: 7.702)

117. Bortezomib in refractory primary plasmacytoma.

Chim CS, Loong F, Ooi C, Au AWM, Lie AKW.

J Clin Oncol 2005; 23(10): 2426-8. (IF: 24.008)

118. Extramedullary cardiac plasmacytoma presenting with cardiac tamponade.

Chim CS, Loong F, Ma SK, Ooi GC.

J Clin Oncol; 23(13): 3140-3, 2005. (IF: 24.008)

119. Bulbar palsy in multiple myeloma.

Chim CS, Ooi GC.

Haematologica, 2005; 90(12 Suppl): ECR42. (IF: 7.702)

120. Long-term outcome of 231 patients with Essential Thrombocythemia: Prognostic

factors for bleeding, thrombosis, myelofibrosis and leukaemia.

28

Chim CS, Kwong YL, Lie AKW, Ma SK, Chan CC, Wong LG, Kho BCS, Lee HK,

Sim JPY, Chan CH, Chan JCW, Yeung YM, Law M, Liang R.

Arch Intern Med 2005; 165: 2651-2658. (IF: 0.815)

121. Eosinophilic leukemic transformation in polycythemia rubra vera.

Chim CS, Ma SK.

Leukemia & Lymphoma, 127: 607-611, 2005. (IF: 2.755)

122. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

Au WY, Lam CCK, Chim CS, Pang AWK, Kwong YL.

Leukemia Research 2005; 29: 1213-1215. (IF: 2.501)

123. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA

in chronic hepatitis B patients who received cytotoxic chemotherapy.

Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, Chim CS, Liang R, Lau

GK.

Blood; 105(6): 2616-7, 2005. (IF: 13.164)

124. Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem

Cell Transplantation with HBsAg Positive Donors.

Hui CK, Lie A, Au WY, Ma SY, Leung YH, Zhang HY, Sun J, Cheung WW, Chim

CS, Kwong YL, Liang R, Lau GK.

Arch Intern Med 2005; 5(6): 1437-45. (IF: 0.815)

125. An epidemiological study of motor neuron disease in Hong Kong.

Fong GC, Cheng TS, Lam K, Cheng WK, Mok KY, Cheung CM, Chim CS, Mak W,

Chan KH, Tsang KL, Kwan MC, Tsoi TH, Cheung RT, Ho SL.

Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6(3): 164-8.

(IF: 2.591)

126. How frequent is SOCS1 methylation in acute myeloid leukaemia?

Chim CS, Kwong YL.

Br J Haematol. 2004 Dec;127(5):609-11. (IF: 5.670)

127. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation

of SHP1 but not SOCS1 in acute leukaemias.


Ann Hematol. 2004 Aug; 83(8): 527-32. (IF: 3.083)

128. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and

monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent

patients.

Au WY, Pang A, Choy C, Chim CS, Kwong YL.

Blood 2004 Jul 1;104(1):243-9. (IF: 13.164)

129. Concurrent hyperreactive malarial splenomegaly and quartan malarial nephropathy -

Plasmodium malariae revisited.

Chim CS, Wong SSY, Poon T, Lam CCK, Chan KW.

29

Haematologica. 2004 Jul; 89(7):ECR21. (IF: 7.702)

130. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic

activation of the Jak/STAT pathway.

Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL.

Blood. 2004 Jun 15;103(12):4630-5. (IF: 13.164)

131. Bull's neck in Hodgkin's disease: a CT imaging appraisal.

Chim CS, Ooi GC.

Haematologica, 2004 May 01;89(5):EIM11. (IF: 7.702)

132. Methylation profiling in multiple myeloma.

Chim CS, Kwong YL, Fung TK, Liang R.

Leuk Res. 2004 Apr; 28(4):379-85. (IF: 2.501)

133. Absence of p300 gene promoter methylation in acute leukemia.


Cancer Genet Cytogenet (Cancer Genetics). 2004 Apr 15; 150(2): 164-7.

(IF: 1.930)

134. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular

lymphoma: implications for epigenetic activation of the Jak/STAT pathway.

Chim CS, Wong KY, Loong F, Srivastava G.

Leukemia. 2004 Feb; 18(2): 356-8. (IF: 11.702)

135. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations

and prognostic impact.

Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ESK, Chan CH, Wong KF, Kwong

YL.

Br J Haematol, 125: 463-469, 2004. (IF: 5.670)

136. Primary Granulocytic Sarcoma of the Mediastinum

Wong WS, Loong F, Ooi GC, Tse TC, Chim CS

Leuk Lymphoma; 45(9):1931-1933, 2004. (IF: 2.755)

137. Primary nasal natural killer cell lymphoma: long-term treatment outcome and

relationship with the International Prognostic Index.

Chim CS, Ma SK, Au WY, Choy C, Lie AKW, Yau CC, Liang R, Kwong YL.

Blood, 103: 216-221, 2004. (IF: 13.164)

138. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and

T-cell lymphoid malignancies in Chinese patients.

Ma SY, Au WY, Chim CS, Lie AK, Lam CC, Tse E, Leung AY, Liang R, Kwong

YL.

Br J Haematol 2004; 124(6): 754-61. (IF: 5.670)

139. Mucosa-associated lymphoid tissue (MALT) lymphoma of the jejunum: an elusive

cause of recurrent upper gastrointestinal bleeding.

Chim CS, Loong F, Chu KM, Ooi GC.

30

Leukemia & Lymphoma; 45(2): 405-7, 2004. (IF: 2.755)

140. Primary Follicular Lymphoma of the Small Intestine.

Chim CS, Loong F, Leung AY, Tsang J, Ooi GC.

Leukemia & Lymphoma; 18(2): 356-8, 2004. (IF: 2.755)

141. Magnetic Resonance (MR) Imaging of Leptomeningeal Lymphoma

Chim CS, Ma ESK, Ooi GC

Br J Haematol; 124(5): 566, 2004. (IF: 5.670)

142. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple

myeloma.

Ma SY, Lie AK, Au WY, Chim CS, Kwong YL, Liang R.

Hong Kong Med J 2004; 10(2): 77-83.

143. Solitary bone plasmacytoma: role of magnetic resonance imaging and positron

emission tomography.

Chim CS, Ooi GC, Loong F, Liang R.

J Clin Oncol, 22: 1328-30, 2004. (IF: 24.008)

144. Cast nephropathy in Multiple Myeloma.

Chim CS, Li FK, Chan G.

Haematologica; 89(4): EIM08, 2004. (IF: 7.702)

145. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.


Ann Hematol. 2003 Dec;82(12):738-42. (IF: 3.083)

146. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in

multiple myeloma and MGUS.


Leukemia. 2003 Dec;17(12):2533-5. (IF: 11.702)

147. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and

prognostic significance.

Chim CS, Wong SY, Kwong YL.

Br J Haematol. 2003 Aug;122(4):571-8. (IF: 5.670)

148. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation

for the treatment of relapsed acute promyelocytic leukaemia.

Au WY, Lie AK, Chim CS, Liang R, Ma SK, Chan CH, Mak YK, Chen YT, So CC,

Yeung YM, Yip SF, Wong LG, Chan JC, Liu SY, Kwong YL.

Ann Oncol; 14(5): 752-7, 2003. (IF: 11.855)

149. Multiple lymphomatous polyposis in lymphoma of colon

Chim CS, Shek TWH, Liang R

J Clin Oncol; 21: 953-955, 2003. (IF: 24.008)

150. Mantle cell lymphoma of the prostate gland

Chim CS, Yau T, Loong F, Liang R.

31

J Clin Oncol; 21: 4456-4458, 2003. (IF: 24.008)

151. Gastrointestinal Manifestations in Mantle Cell Lymphoma

Chim CS, Wayne Wu, Loong F, Ooi GC, Liang R.

Gastrointest Endosc; 58(6): 931-3, 2003. (IF: 6.501)

152. Further analysis of clonality in Kimura’s disease.

Chim CS, Liang R, Fung A, Shek TW, Kwong YL.

Am J Surg Pathol, 27: 703-704, 2003 (IF: 5.363)

153. Can defects in transferrin receptor 2 and hereditary hemochromatosis genes account

for iron overload in HbH disease?

Chan V, Wong MS, Ooi C, Chen FE, Chim CS, Liang RH, Todd D, Chan TK.

Blood Cells Mol Dis; 30: 107-11, 2003. (IF: 1.882)

154. Electronic clinical practice guidelines: current status and future prospects in Hong

Kong.

Chim CS, Cheung NT, Wong KC, Hong F.

Hong Kong Med J; 9: 299-301, 2003. (IF: 1.111)

155. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.


Br J Haematol. 2002 Dec;119(4):988-90. (IF: 5.670)

156. Hypermethylation of gene promoters in hematological neoplasia.

Chim CS, Liang R, Kwong YL.

Hematol Oncol. 2002 Dec;20(4):167-76. Review. (IF:3.118)

157. Real-time quantification of the multidrug resistance-1 gene expression in relapsed

acute promyelocytic leukemia treated with arsenic trioxide.

Au WY, Chim CS, Wai Lie AK, Pang A, Kwong YL.

Haematologica; 87(10):1109-11, 2002. (IF: 7.702)

158. Combined arsenic trioxide and all-trans retinoic acid treatment for acute

promyelocytic leukaemia recurring from previous relapses successfully treated

using arsenic trioxide.

Au WY, Chim CS, Lie AK, Liang R, Kwong YL.

Br J Haematol; 117: 130-132, 2002. (IF: 5.670)

159. Atypical blasts and bone marrow necrosis associated with near-triploid relapse of

acute promyelocytic leukemia after arsenic trioxide treatment.

Chim CS, Lam C, Wong KF, Cornelia Wong, Kam S, Kwong YL.

Hum Pathol; 33(8): 849-51, 2002. (IF: 3.041)

160. Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell

lymphoma and gestational trophoblastic disease.

Au WY, Ma SK, Chung LP, Chim CS, Kwong YL.

Ann Hematol; 81: 659-661, 2002. (IF: 3.083)

161. Acute biphenotypic leukaemia

32

Chim CS, Ma SK


162. Vision-threatening complications of nasal T/NK lymphoma.

Hon C, Kwok AK, Shek TW, Chim JC, Au WY.

Am J Ophthalmol; 134: 406, 2002. (IF:5.052)

163. CNS involvement in CD56-positive intestinal gamma/delta T-cell lymphoma.

Chim CS, Lam CCK, Nicholls J, Ooi GC, Kwong YL.

J Clin Oncol; 20: 3742-3744, 2002. (IF: 24.008)

164. Primary natural killer cell lymphoma of skeletal muscle.

Chim CS, Au WY, Loong F, Ooi GC, Poon C, Choy C, Kwong YL.

Histopathology; 41: 371-4, 2002. (IF: 3.523)

165. Primary skeletal muscle lymphoma.

Chim CS, Choy C, Ooi GC, Gopesh G, Liang R

Am J Med; 112(1): 79-80, 2002. (IF: 5.550)

166. Primary MALT lymphoma of the Gallbladder.

Chim CS, Liang R, Loong F, Chung LP

Am J Med; 112(6): 505-507, 2002. (IF: 5.550)

167. Gut perforation in MALToma of colon.

Chim CS, Shek TWH, Chung LP, Ho J


168. Intravascular lymphomatosis of the prostate gland.

Chim CS, Loong F.

Br J Haematol, 119: 2, 2002. (IF: 5.670)

169. Hemorrhagic Gastric Plasmacytoma as the Primary Presentation in Multiple Myeloma

Chim CS, Wong WM, Nicholls J, Chung LP, Liang R.

J Clin Oncol; 20: 344-347, 2002. (IF: 24.008)

170. Analysis of Clonality in Kimura's Disease.

Chim CS, Alvin, Liang R, Shek TWH, Ho WK, Kwong YL

Am J Surg Pathol; 26(8): 1083-6, 2002. (IF: 5.363)

171. Candida tropicalis fungaemia in adult patients with haematological malignancies:

clinical features and risk factors.

Leung AY, Chim CS, Ho PL, Cheng CC, Yuen KY, Lie AK, Au WY, Liang R,

Kwong YL.

J Hosp Infect; 50: 316-319, 2002. (IF: 3.126)

172. Diagnosis by death.

Tang S, Chim CS, Lai KN.

Ann Intern Med; 137(6): 552-3, 2002. (IF: 17.135)

173. Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic

significance.

33

Chim CS, Tam CY, Liang R, Kwong YL.

Cancer. 2001 Jun 15;91(12):2222-9. (IF: 5.997)

174. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential

diagnostic and prognostic significance.

Chim CS, Liang R, Tam CY, Kwong YL.

J Clin Oncol. 2001 Apr 1;19(7):2033-40.(IF: 24.008)

175. Arsenic trioxide and idarubicin induced remission in relapsed acute promyelocytic

leukemia: clinicopathological and molecular features of a pilot study.

Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R

Am J Hematol; 66 (4): 274-9, 2001. (IF: 5.275)

176. Radiologic manifestations of granulocytic sarcoma in adult leukemia.

Ooi GC, Chim CS, Khong PL, Au WY, Lie AKW, Tsang KWT, Liang R.

Am J Roentol, 176: 1427-1431, 2001. (IF: 2.778)

177. External auditory canal tumor in acute promyelocytic leukaemia: a rare chloroma

with a complete response to arsenic trioxide.

Au WY, CF Chan, Chim CS, Shek TW, Ooi GC, Ho WK, Kwong YL.

J Clin Oncol; 19: 3993-3995, 2001. (IF: 24.008)

178. Chronic Lymphocytic Leukemia involving the Gallbladder.

Chim CS, Loong F, Chung LP

Br J Haematol, 115:717, 2001. (IF: 5.670)

179. Leptomeningeal leukemia masquerading as cauda equina syndrome: appraisal by

magnetic resonance imaging.

Chim CS, Ooi GC.

Haematologica; 86: 1117, 2001. (IF: 7.702)

180. Cerebral Leukostasis manifesting as Multifocal Intracerebral Haemorrhage

Chim CS, Ooi GC


181. Primary CD56 positive lymphomas of the gastrointestinal tract.

Chim CS, Shek TW, Ho J, Liang R, Kwong YL

Cancer, 91:525-533, 2001. (IF: 5.997)

182. Sclerosing malignant lymphoma mimicking idiopathic retroperitoneal fibrosis:

importance of clonality study.

Chim CS, Chan AC, Liang R

Am J Med, 111: 240-241, 2001. (IF: 5.550)

183. Primary Hepatic Lymphoma

Chim CS, Choy C, Ooi GC, Liang R

Leukemia & Lymphoma, 40: 667-670, 2001 (IF: 2.755)

184. Muscle Lymphoma

Chim CS, Au WY, Ooi GC.

34

Lancet, 357: 132, 2001. (IF: 47.831)

185. B-cell Lymphoma of the Gallbladder

Chim CS, Ooi GC


186. Primary Extamedullary Plasmacytoma (EMP) of the lacrimal gland.

Chim CS, Ng IOL, Trendell-Smith NJ, Liang R

Leukemia and Lymphoma, 42: 831-834, 2001. (IF: 2.755)

187. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic

purpura in adult chinese patients-an analysis of 220 cases.

Leung YH, Chim CS, Kwong YL, Lie AKW, Au WY, Liang RHS.

Annals of Haematol, 80(7): 384-386, 2001. (IF: 3.083)

188. Genetic analysis of HLA-typing in Chinese patients with idiopathic thrombocytopenic

purpura (ITP).

Leung AYH, Hawkins BR, Chim CS, Kwong YL, Liang R.

Haematologica 86: 221, 2001. (IF: 7.702)

189. Splenic rupture as the presenting symptom of blastic crisis in a patient with

Philadelphia-negative, bcr-abl-positive ET.

Chim CS, Shek TW, Ma SK, Kwong YL

Am J Haematol, 66: 70-71, 2001. (IF: 5.275)

190. Hemighost cell in acute hepatitis A: glucose-6-phosphate deficiency revisited.

Chim CS, Lam CC, Chan TK

Am J Med, 111: 81-2, 2001. (IF: 5.550)

191. Absence of gallium uptake in multicentric Castleman's disease of plasma cell type.

Chim CS, Choy PT, Kwong YL

Haematologica, 86: 442-443, 2001. (IF: 7.702)

192. Serous degeneration of the bone marrow

Chim CS, Ma SK

Haematologica, 86: 558, 2001. (IF: 7.702)

193. Primary malignant ocular melanoma: a bone marrow diagnosis.

Chim CS, Trendall-smith NJ

Br J Haematol, 112: 2, 2001. (IF: 5.670)

194. CD-30 positive peripheral T-cell lymphoma of the Waldeyer's ring.

Chim CS, Shek WH, Ooi GC, Liang R

Leukemia and Lymphoma. 2000 Jun; 38(1-2):199-202. (IF: 2.755)

195. Nasal T-cell/natural killer cell lymphoma: CT and MR Imaging features of a new

clinicopathologic entity.

Ooi GC, Chim CS, Liang R, Tsang KWT, Kwong YL

AJR American Journal of Roentgenology. 174:1141-5, 2000. (IF: 2.778)

196. Meningeal relapse in Hodgkin’s disease

35

Chim CS, Shek TWH, Ooi GC, Liang R

Journal of Clinical Oncology, 18: 1153-1155, 2000. (IF: 24.008)

197. Pulmonary intravascular lymphomatosis.

Chim CS, Choy C, Ooi GC, Chung LP, Wong KK, Liang R.

J Clin Oncol; 18: 3733-3735, 2000. (IF: 24.008)

198. Hodgkin's Disease with Primary Manifestation in the Liver.

Chim CS, Choy C, Liang R

Leukemia & Lymphoma; 37(5-6): 629-632, 2000. (IF: 2.755)

199. Giant pronormoblasts in parvovirus-associated pure red cell aplasia

Chim CS, Ma SK

Am J Hematol; 65 (4): 289, 2000. (IF: 5.275)

200. Isolated splenic tuberculosis presenting with pyrexia of unknown origin.

Ho PL, Chim CS, Yuen KY

Scand J Infect Dis 32: 700-701, 2000. (IF: 2.201)

201. Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty-year

experience (1975 to 1996).

Chim CS, Liang R, Kwong YL, Lie AKW, Todd D, Chan TK

Aust N Z J Med (Internal Medicine Journal), 25: 726-730, 1999. (IF: 1.902)

202. Outcome of Chinese patients with chronic myeloid leukaemia (CML) underwent

allogeneic bone-marrow transplantation (BMT).

Lee CK, Lie AKW, Liang R, Au WY, Chen FE, Chim CS, Kwong YL

Am. J. Hematol. 61:85-89, 1999. (IF: 5.275)

203. Complex variant 15; 17 translocations in acute promyelocytic leukemia: a case report

and review of three-way translocations.

Wan TSK, Chim CS, So CK, Chan LC, Ma SK

Cancer, Genetics & Cytogenetics (Cancer Genetics); 111(2): 139-431, 1999.

(IF: 1.930)

204. Isolated relapse of acute lymphoblastic leukemia in the breast masquerading as

gynecomastia

Chim CS, Shek WH, Liang R

American Journal of Medicine, 108: 677-679, 1999. (IF: 5.550)

205. Bone Marrow Necrosis Masquerading as Interferon Toxicity in Chronic Myeloid

Leukemia.

Chim CS, Ma Sk, Lam CK

Leukemia and Lymphoma, 33(3-4): 385-388, 1999. (IF: 2.755)

206. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year

experience

Chim CS, Kwong YL, Lie KW, Lee CK, HO FCS, Liang R

American Journal of Hematology, 61 (3), 159-163, 1999. (IF: 5.275)

36

207. CEOP treatment results and validity of the international index in Chinese patients

with aggressive non-Hodgkin's lymphoma.

Chim CS, Kwong YL, Lie AK, Lee CK, Liang Raymond

Hematol Oncol, 16: 117-123, 1999. (IF: 3.118)

208. Computed tomography features of primary pulmonary non-Hodgkin's lymphoma

GC Ooi, Chim CS, Chen F, A Lie, KWT Tsang

Clinical Radiology; 54(7): 438-443, 1999. (IF: 2.478)

209. Lethal Midline Granuloma Revisited: Nasal T/NK cell lymphoma

Chim CS, Ooi GC, Shek WH, Liang R, Kwong YL

Journal of Clinical Oncology, 17: 1322-1325, 1999. (IF: 24.008)

210. Signet Ring Lymphoma of the Bone Marrow

Chim CS, Ma SK, Lam CK, Liang R

J Clin Oncol, 17: 728-729, 1999. (IF: 24.008)

211. Primary follicle center (FCL) lymphoma of the colon.

Chim CS, Choy C, Ooi GC, Liang R.

J Clin Oncol, 17: 3684-3688, 1999. (IF: 24.008)

212. Primary anaplastic large cell lymphoma of skeletal muscle presenting with

compartment syndrome.

Chim CS, Choy C, Liang R

Leukemia and Lymphoma, 33(5-6): 601-605, 1999

(IF: 2.755)

213. Isolated Uterine relapse of T/NK cell lymphoma

Chim CS, Choy C, Liang R, Kwong YL

Leukemia & Lymphoma, 34 (5-6), 629-632, 1999. (IF:2.755)

214. Kimura’s disease: No evidence of clonality

Chim CS, Shek CC, Liang R, Kwong YL

Br J Ophthamol, 83; 878-9, 1999. (IF: 3.806)

215. Castleman’s disease with Kaposi’s sarcoma and glomerulonephritis

Chim CS, Lam KY, Chan KW


216. Cryptococcal infection after fludarabine treatment

Chim CS, Wong SS, Liang R, Yuen KY


217. Herpes simplex encephalitis in multiple myeloma.

Chim CS, Ho PL, Yuen KY, JSM Pieres

Aust N J Med (Internal Medicine Journal), 29:381, 1999. (IF: 1.902)

218. Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia: a

single-centre experience.

37

Au WY, Lie AKW, Ma ESK, Chan LC, Lee CK, Kwong YL, Chim CS, Chan TK,

Chiu E, Liang R.

Hematological Oncology, 16: 163-168, 1998. (IF: 3.118)

219. Mantle Cell Lymphoma in Chinese: clinicopathological features and treatment

outcome.

Chim CS, Choo CK, Chan ACL, Kwong YL, Lie A, Liang Raymond.

American Journal of Hematology, 59: 295-301, 1998. (IF: 5.275)

220. Primary CD30-positive anaplastic large cell lymphoma of the lip.

Chim CS, Chan ACL, Liang Raymond.

European Journal of Cancer. Oral Oncology, 34: 313-315, 1998. (IF: 6.029)

221. Allogeneic bone marrow transplantation for severe aplastic anaemia: the Hong Kong

scenario.

Au WY, Lie AKW, Kwong YL, Chan TK, Chim CS, Lee CK, Chiu EKW, Liang R

Hematological Oncology 16: 41-46, 1998. (IF: 3.118)

222. Bone marrow necrosis in bone marrow transplantation: role of MR imaging.

Chim CS, Ooi C, Ma SK, Lam CK.

Bone Marrow Transplantation , 22: 1125-28, 1998. (IF: 3.874)

223. Hemophilia B in a female carrier due to skewed inactivation of the normal

x-chromosome.

Chan V, Chan VWY, Yip B, Chim CS, Chan TK.

American Journal of Hematology, 58: 72-76, 1998. (IF: 5.275)

224. Reactive Hemophagocytic Syndrome associated with Penicillium marneffei infection.

Chim CS, Fong CY, Ma SK, Wong CY, Yuen KY.

American Journal of Medicine, 104, 196-7, 1998. (IF: 5.550)

225. Fungal Endocarditis in Bone Marrow Transplantation : Case Report and Review of

Literature

Chim CS, Ho PL, Yuen ST, Yuen KY

Journal of Infection, 37: 287-304, 1998. (IF: 4.201)

226. Simultaneous Herpes simplex and Aspergillus fischeri pneumonia in a patient with

multiple myeloma.

Chim CS, Ho PL, Yuen KY.

Scandinavian Journal of Infectious Disease 30: 190-191, 1998. (IF: 2.201)

227. Molecular detection of minimal residual disease in adult and childhood ALL reveals

differences in treatment responses.

Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, Cannell P,

Secker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV.

Leukemia, 1997, 11: 1732-1741 (IF: 11.702)

228. Improved treatment outcome in adult acute lymphoblastic leukemia using the

intensive German protocol, a preliminary report.

38

Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R.

Hematological Oncology, 15 : 19-26, 1997. (IF: 3.118)

229. Deafness in chronic myeloid leukemia.

Chim CS, Woo John.

Leukemia and Lymphoma , 26 : 209-10, 1997. (IF: 2.755)

230. Primary B cell lymphoma of the mediastinum.

Chim CS, Liang Raymond, Chan ACL, Kwong YL, Ho FCS, Todd David.

Hematological Oncology, 14 : 173-9, 1997. (IF: 3.118)

231. Primary cardiac lymphoma.

Chim CS, Chan ACL, Kwong YL, Liang R.

American Journal of Hematology, 54 ; 79-83 : 1997. (IF: 5.275)

232. CD56+ NK lymphomas: clinicopathological features and prognosis.

Kwong YL, Chan ACL, Liang R, Chiang AKS, Chim CS, Chan TK, Todd D, Ho

FCS.

British Journal of Haematology, 97: 821-829, 1997. (IF: 5.670)

233. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma

R Liang, Chen F, Lee CK, Kwong YL, Chim CS, Yau CC, Chiu E.

Bone Marrow Transplantation 1997; 19 : 91-93. (IF: 3.874)

234. Malignant lymphoma masquerading as multiple myeloma.

Chim CS, Ma SK, Leung CY.

Leukemia and Lymphoma, 28 : 607-611, 1997. (IF: 2.755)

235. Reactive Haemophagocytic Syndrome and Hodgkin’s disease.

Chim CS, Hui PK.

American Journal of Hematology, 55 : 49-50, 1997. (IF: 5.275)

236. Polycythemia vera in Chinese patients: thirty-six years of experience.

Chim CS, Kwong YL, Chan PT, Liang Raymond.

American Journal of Hematology, 56 : 59-62, 1997. (IF: 5.275)

237. Unrelated Marrow Donor Registry for Chinese.

Liang Raymond Lee CK, Chen F, Kwong YL, Chim CS, Au WY, Ha SY, ChanCF,

Lau YL.

Chinese Medical Journal, 110, 494-6, 1997. (IF: 1.064)

238. Hemosiderosis with diabetes mellitus in untransfused Hemoglobin H disease.

Chim CS, Chan Vivian, Todd David.

American Journal of Hematology , 57 : 160-163, 1997. (IF: 5.275)

239. Trichostrongylus infestation masquerading as conditioning toxicity of the gut in bone

marrow transplantation.

Chim CS, Luk WK, Yuen KY.

Bone Marrow Transplantation, 19 : 955-958, 1997. (IF: 3.874)

39

240. The use of IgH fingerprinting and ASO-dependent PCR for the investigation of

residual disease (MRD) in ALL.

Chim JCS, Coyle LA, Yaxley JC, Cole-Sinclair MF, Cannell PK, Hoffbrand VA,

Foroni L.

British Journal of Haematology, 1996 ; 92 : 104-115. (IF: 5.670)

241. Molecular analysis of the leukemic B cell in adult and childhood acute lymphoblastic

leukemia.

Coyle LA, Papaioannou M, Yaxley JC, Chim JS, Attard M, Hoffbrand AV, Foroni

L.

British Journal of Haematology, 1996 ; 94 : 685-693. (IF: 5.670)

242. All-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Chim CS, YC Chu, YL Kwong, R Liang, CK Lee, D Todd, TK Chan.

Hematological Oncology, 1996; 14 : 147-154. (IF: 3.118)

243. Cerebellar toxicity with medium dose cytarabine in a young patient with renal

insufficiency.

Chim CS, Kwong YL

American Journal of Hematology, 53 : 208 ; 1996. (IF: 5.275)

f) Conference Papers

1. Epigenetic silencing of tumor suppressor miR-340-5p in multiple myeloma

Zhenhai LI, Chor Sang CHIM. The 59th American Soceity of Hematology meeting.

Atlanta, USA. 9-12, Dec, 2017.

2. Frequent functional activation of RAS signalling not explained by RAS/RAF

mutations in relapsed/refractory multiple myeloma.

Chim CS. Tumor Immunology & Immunotherapy. Cold Spring Habor Asia,

Suzhou, 22-26, Oct, 2017. (Poster)

3. Minimal residual disease detection by ASO RQ-PCR is applicable to 92% of

multiple myeloma using patient-specific primers and probes.

Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung, Chor Sang Chim.

Annual Scientific Meeting of European Society of Hematology, Copenhagen,

2016.

4. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in

chronic lymphocytic leukemia. AACR, New Orleans, 2016 (poster)

Lu Qian Wang, Kwan Yeung Wong, Zhen Hai Li, Chor Sang Chim.


lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT

40

signaling pathways. Frontiers in Cancer Science (FCS), Singapore 2015. (Poster)

Wang LQ, Chim CS

6. 11C-acetate PET/CT predicts 4-year overall survival for patients with newly

diagnosed myeloma. The SNMMI Annual Meeting 2015, Baltimore, Maryland,

June 6-10, 2015. (Abstract)

Sirong Chen, William Cheung, Kam Chau Cheng, Yim Lung Leung, Ka-nin

Wong, CS Chim*, Chi-Lai Ho* (*corresponding author)


lymphocytic leukemia by constitutive activation of MADD/ERK and

PIK3R2/AKT signaling pathways. 35th Congress of the International Society of

Hematology, Beijing, Sep 2014. (Oral Presentation)

LQ Wang, KY Wong, CS Chim

8. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia

- implications on constitutive activation of NF-kappaB pathway. 23rd Biennial

Congress of the European Association for Cancer Research, Munich, Germany, Jul

2014. (poster)

LQ Wang, YL Kwong, CS Kho, KF Wong, KY Wong, M Ferracin, GA Calin and CS

Chim

9. Epigenetic silencing of tumor suppressor miR-3151 in Chinese chronic lymphocytic

leukemia patients. 23rd Biennial Congress of the European Association for Cancer

Research, Munich, Germany, Jul 2014. (poster)

LQ Wang, KY Wong, CS Chim

10. MIR-155-3P IS A TUMOR SUPPRESSIVE MICRORNA FREQUENTLY

SILENCED BY DNA METHYLATION IN MANTLE CELL LYMPHOMA &

OTHER NON-HODGKIN'S LYMPHOMA. 2014 Pan Pacific Lymphoma

Conference, The Fairmont Orchid, Hawaii, Jul 2014. (poster)

Rita LH Yim, Kwan Yeung Wong, YL Kwong, Chor Sang Chim

11. Phase 1 pharmacokinetic (PK) study of Ixazomib citrate (MLN9708) plus

Lenalidomide and Dexamethasone in Asian patients with relapsed/refractory multiple

myeloma (RRMM). 19th Congress of the European Hematology Association, Milan,

Italy, June 2014. (Abstract)

N Gupta, YT Goh, Chang-ki Min, JH Lee, C Suh, K Kim, R Wong, CS Chim, MJ

Hanley, H Yang, K Venkatakrishnan, Ai-Min Hui, C Schusterbauer, WJ Chng

12. Immunoglobulin oligoclonal bands and isotype switching after bone marrow

transplantation in patients with multiple myeloma. 16th Congress of the European

Hematology Association, June 2010

41

Eric Chan, Eric Kwong, WK Ip, CS Chim*



cell transplantation in the treatment of newly diagnosed multiple myeloma. Health

Research Symposium 2010: Improving health and recognising excellence, Hong

Kong Academy of Medicine, the Food and Health Bureau, Hong Kong, Sept 2010.

(Abstract)

Chim CS

14. Epigenetic silencing of miR-203 is a disease initiation event of multiple myeloma.

European Association of Cancer Research, Norway, 2010. (Poster)

KY Wong, DY Jin, R Liang, and CS Chim.



cell transplantation in the treatment of newly diagnosed multiple myeloma. 15th

Congress of the European Hematology Association, June 2010. (Abstract)

Chim CS, Lie AKW, Liang R, Kwong YL.

16. Epigenetic alterations of the miR-34a in hematological malignancies. 15th Congress

of the European Hematology Association. June 2010. (Poster)

Chim CS, Wong KY, Qi Y

17. Epigenetic inactivation of the miR-34a in hematological malignancies. Epigenetics,

Chromatin & Transcription, Suzhou, 2010. (Poster)

Chim CS, Wong KY

18. Induction with sequential Bortezomib/thalidomide/dexamethasone after VAD results

in significant cytoreduction prior to BMT in multiple myeloma. XIth International

Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's

Macroglobulinemia. Greece, June 2007. (Poster)


19. Epigenetic Dysregulation of Wnt Signaling Pathway in Multiple Myeloma. XIth

International Workshop on Multiple Myeloma & IVth International Workshop on

Waldenstrom's Macroglobulinemia. Greece, June 2007. (Poster)

Chim CS, Fung TK, Pang R, Choi CL, Liang R.

20. Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic

leukaemia: an independent poor prognostic factor. 11th Congress of the EHA,

Amsterdam, Netherlands, June 2006. (Poster)

Chim CS, WWL Chan, A Pang, YL Kwong.

21. Long-term outcome of allogeneic bone marrow transplantation (BMT) for 108

42

adult patients with acute lymphoblastic leukaemia (ALL): favorable outcome with

BMT at first remission and HLA-matched unrelated donor. 11th Congress of

Asia-Pacific BMT Meeting, Nogoya, 2006. (Oral presentation)


22. Deferiprone in the treatment of iron overload in patients with HbH disease. 30th

World Congress of ISH 2005, Istanbul, Turkey. (Oral presentation), July 2005

TK Chan, Vivian Chan, Joyce CW Chan, Chim CS, Clara Ooi, B Cheung, RHS

Liang,

23. Epigenetic Dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 Apoptosis

Pathway in Multiple Myeloma : Prognostic value of DAP Kinase methylation. 30th

World Congress of ISH, Turkey, Istanbul, July 2005. (Poster)

Chim CS, R Liang, Fung TK, Kwong YL.

24. Long-term outcomes of 231 patients with Essential Thrombocythemia:

Prognostic factors to bleeding, thrombosis, myelofibrosis and leukaemia. 30th World

Congress of ISH, Turkey, Istanbul, July 2005. (Oral Presentation)

Chim CS, Kwong YL, Lie AKW, Ma SK, Chan CC, Wong LG, Kho BCS, Lee HK,

Sim JPY, Chan CH, Chan JCW, Yeung YM, Law M, Liang R.

25. CIP/KIP methylation in multiple Myeloma. The 10th International Myeloma

Workshop, Sydney, Australia, May 2005. (Poster)


26. Methylation if INK4 and Cip/Kip families of cyclin-dependent kinase inhibitors

in CLL. The 96th Annual Scientific Meeting of American Association of Cancer

Research, Los Angeles, USA, April 2005. (Poster)


27. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute

promyelocytic leukaemia. Chromatin, Chromosomes, and Cancer Epigenetics,

Waikola, Hawaii, Nov 2004. (Poster)

Chim CS, Wong SY, Pang A, Chu P, Kwong YL.

28. SOCS1 AND SHP1 hypermethlation in multiple myeloma: implications for

epigenetic activation of the jak/STAT pathway. 9th EHA annual scientific Meeting,

Geneva, Switzerland, 2004. (Poster)

Chim CS, T.K. Fung, W.C. Cheung, R. Liang, Y.L. Kwong.

29. Efficacy of Bortezomib in Chinese patients with Refractory Myeloma.

Innovation in Cancer, Valencia, Spain, 2004.

Chim CS, AKW Lie, WH Leung, YL Kwong and R Liang.

30. MPD Advisory Board meeting, Melbourne, Australia, 2004.

Chim CS, et al, Essential Thrombocythemia in Chinese: clinical features and

long-term follow-up.

43

31. Methylation Profiling in Multiple Myeloma. 94th Annual Meeting of the American

Association for Cancer Research, Toronto, 2003. (Poster)

Chim CS, Kwong YL, Fung A, Liang R.

32. Primary nasal natural killer cell lymphoma: long-term treatment outcome and

relationship with the International Prognostic Index. 45th Annual Scientific Meeting

of the American Society of Hematology, San Diego, 2003 (Poster)

Chim CS, Ma SK, Au WY, Choy C, Lie AKW, Yau CC, Liang R, Kwong YL.

33. Can defects in transferrin receptor 2 and hereditary hemochromatosis genes account

for iron overload in HbH disease? Annual Scientific Meeting of the International

Society of Haematology, Seoul, 2002.

Chan V, Wong MS, Ooi C, Chen FE, Chim CS, Liang RH, Todd D, Chan TK.

34. Coinheritance of HFE and TFR2 defects in HbH disease in the Chinese.

Wong MS, Chim CS, Liang RHS, Todd D, Chan TK, Chan V. 7th Medical Research

Conference, University of Hong Kong, 2002.

35. Gleb Baida, Chim CS, Helen Pomykala, Diana M. Roulston, Richard A. Larson,

Olufunmilayo I. Olopade. LUN, a novel transcription factor on 9p21 Is frequently

deleted in human leukaemia. Medicine, University of Chicago, Chicago, IL;

Medicine, University of Hong Kong, Hong Kong, China; Pathology, University of

Michigan, Ann Arbor, MI. BLOOD 98 (11): 98A-99A 412 Part 1, NOV 16, 2001

36. Mutations of the HFE gene for hereditary hemochromatosis in Southern Chinese

with iron overload. Medical research meeting, University of Hong Kong, 2001.

Wong MS, Chan TK, Lam KC, Chim CS, Chan V.

37. Genetic and clinical features of hemoglobin H disease in Chinese patients: the

sequela.

Chen FE, Chim CS, Ooi C, Ha SY, Todd D, Chan TK, Chan V. Medical forum,

University of Hong Kong, 2001.

38. Methylation profiling in acute leukaemia.

Chim CS, Liang R, Wong AW, Kwong YL. Cancer & chromosomal organization:

Epigenetics of cancer, 2001.

39. P15 and p16 gene methylation in adult acute leukemia.

Chim CS, Tam CYY, Liang R, Kwong YL. 42th Annual Meeting of the American

Society of Hematology, San Francisco, 5-9th, Dec, 2000.

40. Donor lymphocyte infusion (DLI) for leukemia relapse: a revisit. Medical

Research Conference 2000, Department of Medicine, University of Hong Kong, Jan,

2000.

Au WY, Lie AKW, Kwong YL, Lee CK, Chim CS, Leung YH, Liang R.

41. ICE/BEAM chemotherapy and peripheral blood stem cell rescue for relapse after

bone marrow transplantation.

44

Au WY, Lie AKW, Lee CK, Liang R, Chim CS, Leung YH, Kwong YL. Medical

Research Conference 2000, Department of Medicine, University of Hong Kong, Jan,

2000.

42. Asenic trioxide and idarubicin induced remissions in relapsed acute promyelocytic

leukemia: clinicopathological and molecular features.

Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Medical Research

Conference 2000, Department of Medicine, University of Hong Kong

43. CT and MR imaging in nasal NK/T cell lymphoma: Lethal midline granuloma

reclassified.

Ooi GC, Chim CS, Liang R, Tsang KWT, Kwong YL. 7th Annual Scientific Meeting,

Hong Kong College of radiologists, Oct, 1999 & Radiology 2000- Imaging, Oncology

& Science: Br J Radiology, poster 702, pp72, 2000

44. Review of the use of colony-stimulating factors in the treatment of cancer. The

6th Hong Kong International Congress of Cancer, Nov, 1999.

Chim CS

45. Treatment Outcome of Adult Acute Lymphoblastic Leukemia (ALL) in Chinese with

an Intensive German Protocol.

Chim CS, Liang R, Chan YT, Lie AKW, Chu YC, Chan CH, Ma SK, Wong KF,

Chan LC, Lee CK, Au WY, Kwong YL. 41th Annual Meeting of the American

Society of Hematology, New Orleans, 1999-11-11.

46. Fludarabine in the treatment of low grade lymphoproliferative disorders.

Kwong YL, Chim CS, Au WY, Lee CK, Lie AKW, Liang R. Medical Research

Conference, Department of Medicine, University of Hong Kong, Jan, 1999

47. Treatment for post bone marrow transplant relapse of chronic myeloid leukemia

using donor buffy coat with or without interferon-.

AKW Lie, YL Kwong, Lee CK, Chim CS, Au WY, Cahn YET, Liang R. Medical

Research Conference 1999, Department of Medicine, The University of Hong Kong,

Queen Mary Hospital, Hong Kong.

48. Minimal residual disease (MRD) in acute promyelocytic leukemia.

Au WY, Lie AKW, Lee CK, Chim CS, Liang R, Kwong YL. Medical Research

Conference 1999, Department of Medicine, The University of Hong Kong, Queen Mary

Hospital, Hong Kong.

49. Advanced stage and unfavorable Hodgkin’s disease in Hong Kong.

Chim CS, Kwong YL, Lie AKW, Lee CK, Liang R. 40th Annual Meeting of American

Hematology Society, December 1998, Blood

50. Outcome of AML patients receiving allogeneic BMT using busulphan,

cyclophosphamide and total body irradiation (Bu-Cy-TBI) as conditioning regimen.

Lee CK, Lie AKW, Chim CS, Au WY, Kwong YL, Liang R. 40th Annual Meeting of

American Hematology Society, December 1998, Blood

45

51. Natural killer cell lymphoma/leukemia: clinicopathogical features, treatment and

prognosis.

Kwong YL, Chan ACL, Chim CS, Lie AKW, Liang R. The fifth Hong Kong

International Cancer Congress, Nov, 1998

52. Computed tomography features of primary pulmonary non-Hodgkin’s

lymphoma.

Ooi CGC, Chim CS, Chen F, Lie A, Tsang KWT.

Hong Kong Academy of Medicine: First International Congress, 26-29 Nov, 1998

53. Higher incidence of bcl-6 gene hypermutations in diffuse large B-cell lymphoma of

extranodal origin.

Liang R, Au WY, Lee CK, Chim CS, Lie AKW, Kwong YL. 27th International Society

of Haematology Congress, July 1998.

54. Immune clearance of serum hepatitis B surface antigenaemia following allogeneic

bone marrow transplantation : vaccination versus natural immunity.

Liang R, Lau GKK, Au WY, Lee CK, Chim CS, Lie A, Chen F, Kwong YL. 34th

Annual Meeting of the American Society of Clinical Oncology. May, 1998,

abstract No. 326.

55. BCL-6 gene rearrangement and mutations in diffuse large B-cell lymphoma

(DLBCL) of nodal and extranodal origin.

Liang R, Xu WS, Au WY, Fung A, Chan A, Lee CK, Chim CS, Lie AKW, Kwong YL,

Srivastava G. Department Research Meeting, University of Hong Kong.

56. Allogeneic bone marrow/stem cell transplant and hepatitis B infection.

Liang R, Lau GKK, Lie A, Chen F, Au WY, Lee CK, Chim CS, Kwong YL. 5th

Congress of the Asian Society of Transplantation. December 1997, No.477, p520.

57. Allogeneic bone marrow transplantation for acute myeloid leukaemia in Hong

Kong.

Au WY, Lie AKW, Lee CK, Chan TK, Chiu E, Kwong YL, Chim CS, Chen FE, Liang

R. 14th Asian Pacific Cancer Conference, November, 1997, No. P.8.

58. Allogeneic bone marrow transplantation for patients with chronic myeloid

leukaemia in Hong Kong.

Lee CK, Lie AKW, Liang R, Chiu EKW, Chen FE, Chim CS,. 14th Asian Pacific

Cancer Conference, November, 1997, No.73.4 (major author)

59. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: the

Hong Kong experience.

Au WY, Lie AKW, Lee CK, Chan TK, Chiu E, Kwong YL, Chim CS, Chen FE, Liang

R. 14th Asian Pacific Cancer Conference, November 1997. No. 69.7.

60. Bone marrow transplantation and hepatitis B infection.

Liang R, Lau GKK, Lie AKW, Chen F, Lee CK, Au WY, Kwong YL, Chim CS.. 14th

Asian Pacific Cancer Conference, November 1997, No. 19.3.

46

61. Peripheral blood stem cell harvest in Hong Kong Chinese.

Au WY, Lie AKW, Chan FE, Kwong YL, Lee CK, Chim CS, Chan TK, Liang R. 5th

International Blood Cell Transplantation Symposium, October, 1997.

62. Bone Marrow Transplantation and hepatitis B infection.

Liang R, Lau GKK, Chen F, Lee CK, Au WY, Kwong YL, Chim CS. 33rd annual

meeting of the American Society of Clinical Oncology, May 1997, abstract No. 312.

63. Effect of bone marrow transplantation on chronic hepatitis B infections.

Liang R, Lau G, Kwong YL, Chen F, Lee CK, Chim CS. 7th International Congress on

anti-cancer treatment. Feb 1997, 128 .

64. CD56+ malignant lymphoma: identification of clinico-pathological subtypes with poor

prognosis.

Kwong YL, Chan ACL, Liang R, Chim CS, Chiang AKS, Chan TK, Todd D, Ho FCS.

38th Annual meeting of the American Society of Hematology. December 1996, No.

891. Blood 88: A891, 1996.

65. Polycythaemia rubra vera in Chinese.

Chim CS, Kwong YL, Chan PT, Liang R. 38th Annual Meeting of American Society of

Hematology. December 1996, No. 3542. Blood 88: A3542, 1996.

66. Bone marrow transplants using matched unrelated donor for Chinese patients with

leukaemia and lymphoma.

Lee CK, Liang R, Chiu E, Chen F, Kwong YL, Chim CS, Ha SY, Lau YL, Hawkins

BR, Chan TK. Consensus conference on unrelated donor - bone marrow transplantation,

Royal College of Physicians of Edinburgh, October 1996, P2, page 24.

67. Chemotherapy for intermediate grade lymphoma using 4 different

doxorubicin-containing regimens.

Liang R, Todd D, Kwong YL, Chim CS, Lee CK, Ho FCS.

6th International Conference on Malignant Lymphoma. June 1996, 573.

68. Bcl-6 gene rearrangement in Hodgkin's and non-Hodgkin's lymphoma in Hong

Kong Chinese.

Liang R, Chan WP, Kwong YL, Chim CS, Lee CK, Todd D, Chan A, Ho FCS. 32nd

Annual Meeting of the American Society of Clinical Oncology, May 1996, 1307.

69. Autologous bone marrow transplantation for primary T-/NK-cell nasal lymphoma.

Liang R, Lee CK, Chim CS. 4th International Symposium on Hematopoietic Stem Cell

Transplantation, April 1996, p234.

70. Bcl-6 gene rearrangement in Hong Kong Chinese patients with lymphoma.

Liang R, Chan WP, Kwong YL, Chim CS, Lee CK, Chan A, Ho FCS. 37th Annual

Meeting of American Hematology Society, December 1995. Blood 86: 3254, 1995.

71. Absence of factor V gene mutation (1691 G to A) in Hong Kong Chinese patients

with deep vein thrombosis (DVT).

47

Lee CK, Chan WP, Liang R, Kwong YL, Chim CS, Todd D, Chan TK. 37th Annual

Meeting of American Hematology Society, December 1995, Blood 86 : 3665, 1995.

72. All-trans-retinoic-acid for acute promyelocytic leukaemia - the Hong Kong Scenario.

37th Annual Meeting of American Hematology Society, December 1995, No. 3000.

Chim CS, Chu YC, Liang R, Kwong YL, Lee CK, Todd D, Chan TK.

73. All-trans retinoic acid in the treatment of acute promyelocytic leukemia: The Hong

Kong Scenario.

Chim CS, YC Chu, YL Kwong, R Liang, CK Lee, D Todd, TK Chan. Blood

p.753a, Vol 86, No.10, Suppl I, 1995.

74. BCL-6 gene rearrangement in Hong Kong Chinese patients with lymphoma.

R Liang, WP Chan, YL Kwong, Chim CS, CK Lee, A Chan, FCS Ho. Blood

p.817a, Vol 86, No.10, Suppl I, 1995.

75. Absence of Factor V gene mutation (1691 G to A) in Hong Kong Chinese patients

with deep vein thrombosis (DVT).

CK Lee, WP Chan, R Liang, YL Kwong, Chim CS, D Todd, TK Chan. Blood

p.919a, Vol 86, No.10, Suppl I, 1995.

76. Molecular detection of minimal residual disease (MRD) in adult and childhood all

reveals differences in treatment response.

L Foroni, LA Coyle, JC Yaxley, M Papaioannou, MF Cole Sinclair, Chim CS, PK

Cannell, AB Mehta, HG Prentice, AV Hoffbrand. Blood p.330a, Vol 86, No.10,

Suppl I, 1995.

77. Molecular analysis of the leukemic B cell in adult and childhood acute lymphoblastic

leukemia.

L Foroni, LA Coyle, JC Yaxley, M Papaioannou, Chim CS, A Victor Hoffbrand.

Blood p.728a, Vol 86, No.10, Suppl I, 1995.

78. Comparative Study of four PCR-based methods in the study of minimal residual

disease in B-lineage acute lymphoblastic leukemia.

Chim CS, AV Hoffbrand, L Foroni. Hong Kong International Cancer Congress,

1994.

79. To study the variable (v) gene, diversity (D) gene and joining region (J) gene usage

in B-lineage acute lymphoblastic leukemia.

Chim CS, AV Hoffbrand, L Foroni. Hong Kong International Cancer Congress,

1994.

80. Minimal residual disease (MRD) analysis of Adult and children ALL.

L Coyle, M Cole-Sinclair, Chim CS, P Cannell, F Wright, AB Metha, HG Prentice,

AV Hoffbrand, L Foroni. Blood p.300a, Vol 84, No. 10, Suppl I, 1994.

81. A Rapid Method for the detection of clonal B cell expansion and reaction (PCR).

L Foroni, JC Yaxley, Chim CS, AV Hoffbrand and P Amlot. Blood, Vol 82, No.

10, Suppl I, 1993.

48

g) Local publications:

1. JCS Chim. Cancer Treatment in the Era of Targeted Therapy: the March is on!

Hong Kong Medical Diary, p.2-3, March issue, 2011.

2. JCS Chim. To Optimise Myeloma Treatment in the Era of Targeted Therapy. P7-9.

March issue, 2011

3. JCS Chim. Demethylation Therapy in Haemic Cancer. Hong Kong Medical Diary,

p.2-3, Aug issue, 2008

4. JCS Chim. Epigenetic Therapy Comes of Age: Waking Up Silenced Tumour

Suppressor Genes in Myelodysplastic Syndrome. Hong Kong Medical Diary, p.5-8,

Aug issue, 2008

5. Chim CS. Editorial: Molecular targets of therapy in haemic cancers. The Hong Kong

Medical Diary. 12 (4), April 2007: 2-3.

6. Chim CS. Review: Advances in the treatment of multiple myeloma: long awaited. The

Hong Kong Medical Diary. 12 (4), April 2007: 6-8.

7. Chim CS. HK Blood Cancer Group Newsletter: Jan, 2007

49

(ii) Research Grants/Post-Doc Fellow

(a) Competitive Grants:

Research Title Role Grant Source Date of Grant

Identification of methylated

microRNAs in acute promyelocytic

leukaemia & their potential clinical

application

PI HMRF (HKD996,808) 2016-2018

Mechanism study of the effect of

microenvironment on RANKL

expression in myeloma cells

PI

NSFC (CNY75.0000)

2015-2018

Functional study of the impact of

hypermethylation of tumor

suppressive mico-RNA in myeloma

stem cells

PI

RGC (HKD944,700)

2010-2012

Study of methylation of microRNA

in mantle cell lymphoma

PI RGC (HKD800,000) 2012-2014

(b) Post-doc fellow awarded by the Hong Kong Scholars Program/HKU:

2012 - 2015: Dr Allen Yuan Ling Ching

2015 - 2017: Dr Liu Xiaoping

(c) Non-RGC Grant

Research Title Role Grant Source Date of

Grant

Methylation of miR-224 in

haematological cancers

PI HKU Seed Funding

HKD51,000

2012-2014

Hong Kong Blood Cancer Foundation

– Gene Methylation in Myeloma

PI Hong Kong Blood

Cancer Foundation

HKD1,210,240

2011-2015

The role of aberrant promoter

methylation of tumor suppressor

micro-RNA in chronic lymphocytic

leukemia (CLL)

PI HKU Seed Funding

HKD120,000

2008-2010

Study of tumor suppressor function

of miR-124a in non-Hodgkin's

lymphoma

PI HKU Seed Funding

HKD70,000

2009-2011

50

FISH study and the use of

bortezomib in high-risk multiple

myeloma

PI Lee Hysan Foundation

HKD1,050, 000

2008-2011

Study of epigenetic inactivation of

ATM gene in mantle cell lymphoma

Co-I Seed Funding, HKU

HKD68,000

2003-2005

Methylation in haemic cancer PI UDM, HKU

HKD200,000

2000-2002

p15 & p16 methylation

Co-I CRCG

HKD106,000

1998-2000

PI: Principal Investigator, Co-I: Co-investigator

51

(E) Invited Lectures and Advisory Board Meetings

(i) International or Regional Lectures

11/2017 Outlook of Myeloma Management, Asean Multiple Myeloma (MM)

Workshop, Singapore, 11, Nov 2017

10/2017 Monoclonal Antibodies in Multiple Myeloma, the First Asian Myeloma

Network Meeting, Seoul, 13-15, Oct, 2017

9/2017 Proteasome inhibitors in multiple myeloma: the 3rd Union International

Summit on Lymphoma & Myeloma, Tianjin, 22-23, Sep, 2017

5/2017 Multiple myeloma – MRD by Freelite Chain/Heavylite. Beijing Myeloma

Summit 2017 in Beijing, 12-13 May 2017

3/2017 Management of relapsed and refractory multiple myeloma (RRMM).

Highlight of American Society of Hematology (ASH) 2017 in Asia Pacific,

Hong Kong, 10-12 Mar 2017

1/2017 Choice of therapy for relapsed myeloma. 8th International Hematologic

Malignancies Conference: Bridging the Gap (BTG 2017), Bangkok, 12-14

Jan 2017

12/2016 Novel criteria for diagnosing multiple myeloma and their therapeutic

implications. European Society for a Medical Oncology (ESMO) Asia

Congress 2016, Singapore, 16 – 19 Dec 2016

09/2016 “Immunotherapy in myeloma: Facts or Fiction?”, Cross-Strait Hematology

Summit, Fuzhou, China, 10-11 Sep 2016

08/2016 "Immunotherapy in myeloma & the Immunosuppressive

micro-environment", in B Cell Malignancies meeting, Seoul, Korea, 27-28

Aug 2016

03/2016 The standardized treatment and updated clinical trial of myeloma in HK. (1)

First Affiliated Hospital of Nanjing Medical University, (2) Nanjing

General Hospital of Nanjing Military Command (Jinling Hospital) in

Nanjing, & (3) Second Affiliated Hospital (Xinqiao Hospital) of the Third

Military Medical University (中国人民解放军第三军医大学) & (4)

Chongqing Medical University affiliated Hospital in Chongqing, Nanjing &

Chongqing, China, 25 – 29 Mar 2016

02/2016 Optimal induction therapy for newly diagnosed transplant eligible myeloma?

7th International Hematologic Malignancies Conference: Bridging the Gap

(BTG 2016), Guangzhou, China, 26 - 28 Feb 2016

01/2016 Unmet Medical Needs in Multiple Myeloma: The ASEAN Perspective.

Multiple Myeloma Workshop, Hong Kong, 30 Jan 2016

52

10/2015 Monitoring of myeloma: Role of minimal residual disease. 2nd Asia Pacific

B-cell Malignancy Meeting, Hong Kong, Oct 2015

09/2015 Unmet Medical Need in myeloma in Asia-Pacific: the example of

transplant-eligible myeloma in HK receiving bortezomib-based induction.

Multiple myeloma investigator meeting, Janssen, Rome, Italy, Sep 2015

09/2015 Cross-Strait Hematology Summit, Fuzhou, China, 11-13 Sep 2015

05/2015 Optimal Induction regimens in myeloma, The 1st West China International

Haematological Malignancy Summit, Chengdu, Sichuan, China, 21-24 May

2015

03/2015 DNA methylation of tumor suppressive microRNA in myeloma, 5th Clinical

Epigenetics International Meeting, Düsseldorf, Germany, 5-6 Mar 2015

01/2015 Optimal induction in Myeloma: Doublet vs. Triplet, 6th International

Hematologic Malignancies Conference: Bridging the Gap (BTG 2015),

Beijing, China, 30 Jan – 1 Feb 2015

09/2014 Immunotherapy of multiple myeloma, XXXV World Congress International

Society of Hematology (ISH), Beijing, China, 4-7 Sep 2014

08/2014 Cross-Strait Hematology Summit, Fuzhou, China, 8-10 Aug 2014

05/2014 Immunomodulation and cell therapy, The World Congress in Controversies

in Multiple Myeloma, Thailand, 11-13 May 2014

02/2014 Prospects of Immunotherapy in myeloma, 4th International Hematologic

Malignancies Conference: Bridging the Gap (BTG 2014), Taipei, Taiwan,

14-15 Feb 2014

10/2013 Epigenetic Alterations in multiple myeloma and/or The Myeloma Study in

Hong Kong, 1st Union Summit Forum on Lymphoid Malignancies, Tianjin

China, 17-20 Oct 2013

10/2013 Transplant-eligible Myeloma: What is the next clinical question?, 15th

Beijing/Hong Kong Medical Exchange - Recent Advances in Cancer

Medicine, Hunan, China, 12-13 Oct 2013

09/2013 Management of Myeloma in countries with limited access to novel agents,

4th Conference of Myanmar Society of Haematology, Myanmar, 28-29 Sep

2013

08/2013 Advances in Myeloma Treatment, 3rd Annual Updates on Breakthroughs in

Hematology (AUBH2013), Thailand, 30-31 Aug 2013

04/2013 Myeloma in Hong Kong, International Myeloma Workshop, Kyoto, 2013

02/2013 Optimal Therapy for Relapsed/ Refractory Myeloma, 3rd International

Hematologic Malignancies Conference: Bridging the Gap (BTG 2013), Hong

Kong, 22-23 Feb 2013

12/2012 microRNA methylation in myeloma, International Conference on Genomics,

Beijing Cancer Institute, Hong Kong, Dec 2012

53

10/2012 Guangzhou Hematology Frontier Forum, Sun Yat-sen Institute of

Hematology, 19-20 Oct 2012

07/2012 Treatment of transplant-eligible myeloma in Hong Kong: from the staged

approach to frontline bortezomib, 10th Annual Meeting of Japanese Society

of Medical Oncology (JSMO), 26-28 Jul 2012

02/2012 Methylation of tumor suppressor microRNAs in multiple myeloma, Bridging

the Gap, 3rd International Hematologic Malignancy Conference, jointly

organized by the MD Anderson Cancer and the University of Hong Kong

01/2012 Methylation of tumor suppressor genes in multiple myeloma, Croucher

Advanced Study Institute, 9-13 Jan 2012

03/2011 Epigenetics in Myeloma, Bridging the Gap, 2nd International Hematologic

Malignancy Conference, jointly organized by the MD Anderson Cancer and

the National University of Singapore

10/2010 Gene hypermethylation in hematological Cancers

PLA 301 Hospital, Beijing

09/2010 How to Manage NK-cell Lymphoma

Annual Convention : The Philippine Society of Hematology and Blood

Transfusion, Manila, Philippines

07/2010 Gene hypermethylation in hematological Cancers

Peking Union Medical College Hospital, Beijing

04/2010 Management of refractory myeloma

第七届全国难治性白血病学术研讨会、第二届全国难治性淋巴瘤学术

研讨会暨第三届全国多发性骨髓瘤学术研讨会-贵州

01/2010 NK/T-cell lymphoma

Post-American Society Hematology Conference : Current Trends in

Leukemia, Lymphoma and Myeloma, New York, USA

01/2010 Epigenetic alterations of microRNA in hematological cancers

Quangzhou

11/2009 Epigenetic regulation of miRNA expression in hematological malignancies

RNA Silencing 2009: Mechanisms and Applications, Croucher

Foundation-sponsored Conference, Hong Kong

06/2009 The Emerging Role of Novel Therapies in the Treatment of Multiple

Myeloma & Hong Kong Experience

Multiple Myeloma expert meeting, Taiwan

(Taipei : Chang Gung Memorial Hospital–Linkou, Taipei Veteran’s

General Hospital and National Taiwan University Hospital)

06/2009 Multiple Myeloma : The Past, the present & the future

Visiting Professorship Awarding Ceremony, Wuhan, China

04/2009 Myeloma - Past, Present and Future

54

Hong Kong-Beijing-Hangzhou Medical Forum 2009, Hangzhou, China

11/2008 建立在危險度評價基礎上的惡性血液病分層次治療

南方醫科大學珠江醫院

11/2008 Recent Advances in Targeted Therapy of Haematological Malignancies

15th Hong Kong International Cancer Congress, Hong Kong

11/2008 Gene hypermethylation in haemic cancers

10th Chinese National Hematology Conference, Tongji Hospital Affiliated

to Tongji Medical College Huazhong University of Science and Technology

(HUST), Wuhan, China

10/2008 Gene hypermethylation in haemic cancers: prognostic and therapeutic

implications

Nanfong Hospital, Guangzhou, China

10/2008 Multiple Myeloma : The Past, the present & the future

The First Clinical College of Harbin Medical University, Heilongjiang

Province, China

09/2008 Multiple Myeloma: the past, the present and the future

廣州抗癌協會血液腫瘤專業委員會

05/2008 Defeating Leukaemia and Multiple Myeloma 治療骨髓癌及白血病新知

1st series of Public Lecture Series 2008, The University of Hong Kong

03/2008 Essential Thrombocythemia: risk factors to thrombosis, bleeding

myelofibrosis and leukemia

南方醫科大學珠江醫院

11/2007 Epigenetic alterations in the pathogenesis of multiple myeloma

Hong Kong International Cancer Congress

10/2007 Targeted therapy in Haemic malignancies

Annual Scientific Meeting of the Federation of Medical Societies of Hong

Kong

08/2007 Impact of allogeneic bone marrow transplantation in adult ALL

Nanfong Hospital, Guangzhou, China

07/2007 Epigenetic alterations in haemic cancers,

Cancer Centre, University of Hong Kong

07/2007 Emerging concepts in the management of multiple myeloma

Centro Hospitalar Conde de S. Januario, Macau

06/2006 Aberrant gene promoter methylation in haemic cancers

Joint Hong Kong-Guangzhou Medical Forum, Guangzhou, China

05/2006 Aberrant gene promoter methylation in haemic cancers

Asia Pacific MDS Expert Meeting, Jeju, Korea

11/2005 Gene Hypermethylation in haemic cancers: Profile & Significance,

Frontiers in Biomedical Research, University of Hong Kong

55

11/1999 Lecture: Review of the use of colony-stimulating factors in cancer

The 6th Hong Kong International Cancer Congress

56

(ii) Advisory Board Meetings

Date Advisory Board Venue Hosted by

5 Dec 2016 – 31

Dec 2019

Takeda – Emerging Markets Steering Committee

Meetings

Various Takeda

Pharmaceuticals

International AG

12 Mar 2017 Takeda Ixazomib Advisory Board Meeting Hong Kong Takeda

Pharmaceuticals

International AG

2 Jul 2016 Janssen B-Cell Malignancies Advisory Board

Meeting Multiple Myeloma

Taipei, Taiwan Janssen Asia

Pacific, a

Division of

Johnson &

Johnson Pte Ltd

12 Jun 2016 Takeda Unmet needs in MM management –

Emerging Markets Advisory Board Meeting

Copenhagen,

Denmark

Takeda

Pharmaceuticals

International AG

10 Jun 2016 Celgene Asia Pacific NDMM Advisory Board

Meeting

Copenhagen,

Denmark

Celgene Pte Ltd

9 Apr 2016 1st Janssen Asian Expert Forum Beijing, China Xian Janssen

Pharmaceutical

Ltd.

24-29 Mar 2016 Janssen China Speaker Tour Nanjing &

Chongqing, China

Xian Janssen

Pharmaceutical

Ltd.

19 Mar 2016 Takeda 2nd Ixazomib advisory board meeting/

Singapore

Singapore Takeda

Pharmaceuticals

(Hong Kong)

Limited

4 Dec 2015 Telephone Interview for Myeloma Therapies of

Tomorrow

Hong Kong Healthcare

Research &

Analytics

28 Nov 2015 Amgen's Regional Advisory Board (Multiple

Myeloma)

Seoul, South Korea Amgen Asia

Holding Limited

19 Nov 2015 NowTV 杏林在線 NOW TV studio,

Wanchai, HK

NowTV

24-25 Oct 2015 Chaired & Presented at Janssen 2nd Asia Pacific

B-Cell Malignancies Meeting

Hong Kong Janssen Asia

Pacific, a

Division of

57

Johnson &

Johnson Pte Ltd

17 Oct 2015 Takeda Ixazomib APAC/GC Advisory Board Singapore Takeda

Pharmaceuticals

International

GmbH

25 Sep 2015 Janssen forthcoming Multiple Myeloma

Investigator Meeting during IMW 2015

Rome, Italy Janssen

Pharmaceutical

Company of

Johnson &

Johnson

23 Sep 2015 Adviser of Celgene Asia Pacific Multiple Myeloma

Ad Board during IMW 2015

Rome, Italy Celgene Pte Ltd

10 Jun 2015 Novartis 2015 EHA Joint Region Europe EGM

Multiple Myeloma Advisory Board

Vienna,Austria Novartis

Pharmaceuticals

(HK) Limited

6 December 2015 MM Round Table Meeting during American

Society of Hematology (ASH) 2014

San Francisco, US The Medal Group

5th December

2014

Millennium/Takeda American Society of

Hematology (ASH) 2014 Advisory Discussion -

Multiple Myeloma

San Francisco, US Millennium

Pharmaceuticals,

Inc.

7th December

2014

Pomalyst Advisory Board Meeting during

American Society of Hematology (ASH) 2014

San Francisco, US Celgene Pte Ltd

28-31 Oct 2014 Delivered lectures to the doctors and students in

the Affiliated Hospital of Xuzhou Medical College

China The Affiliated

Hospital of

Xuzhou Medical

College

1-2 Nov, 2014 APECHO 2014 - Haematological Malignancy

Stream

Shanghai, China Novartis

Pharmaceuticals

(HK) Limited

14 Jun 2014 Novartis Region Europe & Emerging Growth

Markets Advisory Board Meeting for Panobinostat

in Multiple Myeloma at EHA

Milan, Italy Novartis Pharma

AG

27 Oct 2013 Asia Pacific Multiple Myeloma Expert Roundtable China Janssen - division

of Johnson &

Johnson Pte Ltd

10-13 Oct 2013 Speaker in Suzhou International Clinical Forum

2013

China Soochow

University -

Jiangsu Institute

58

of Hematology

3 April 2013 Consultant in Millennium Advisory Board Meeting

at the International Myeloma Workshop 2013

Japan Millennium

Pharmaceuticals,

Inc.

3 April 2013 Janssen Asia Pacific Myeloma Advisory Meeting Japan Janssen, a

division of

Johnson &

Johnson Pte Ltd

22 February 2013 Chairman of the Celgene Symposium at Bridging

the Gap 2013

Hong Kong Celgene Pte Ltd

23-25 February

2012

Chairman of Bridging the Gap 2012 Hong Kong The Medal Group

Corp

23 Feb 2012 Chairperson and moderator during the Celgene

Lunch Symposium - Bridging the Gap 2012

Hong Kong Celgene Pty Ltd.

25 Feb 2012 The Multiple Myeloma Advisory Board in

Bridging the Gap 2012

Hong Kong. The Medal Group

Corp

12 Sep 2011 Provided expert advice on the research

proposal:”Biomarker development for effective

immunomodulatory therapy in multiple

myeloma”

Hong Kong Agency for

Science,

Technology and

Research

(A*STAR)

28 Aug 2011 Takeda Advisory Board meeting Hong Kong Millennium: The

Takeda Oncology

Company

27 Mar 2011 Chairperson at the 3rd Celgene Asia-Pacific Expert

Meeting

Hong Kong Celgene Limited

17 Mar 2011 VELCADE ASIA Pacific Advisory Board Singapore Janssen

Pharmaceutica

03 Sep 2010 Participation for CAPEM Steering committee

Meeting and Autumn Lecture Tour by Prof.

Dimopoulos

Korea Celgene Ltd

15 & 16 May 2010 Guest Speaker for the Asia Pacific Myeloma

summit Hematology hosted CME Meeting

Hong Kong Janssen

Pharmaceutica

27-28 Feb 2010 Chairperson for CAPEM (Celgene Asia Pacific

Expert Meeting) 2010

Korea Celgene Ltd.

30 Jan 2010 Faculty member for the Current Trends in

Leukemia, Lymphoma and Myeloma program

United State Physicians'

Education

Resource

59

Teaching (i) Supervision & Examiner of Graduate student

PhD students year year of

graduation

remark

Wong Kwan Yeung 2009-2012 31/8/2012 graduated

Rita Yim 2011-2014 31/8/2014 graduated

Lucy Wang 2011-2015 30/4/2015 graduated

Bai Yinlei 2013-2017 31/12/2017

Li Zhenhai 2013-2017 31/3/2018

Zhang Minyue 2014-2018 31/8/2018

Wang Qiumei 2016-2020 31/8/2020

a) Supervision of students

1. Principal Supervisor:

Ph.D. student: Mr Wong Kwan Yeung

Topic: “Role of methylation of microRNA in multiple myeloma”

(Since 2008, Sep – Sep, 2011)


Ph.D. student: Luqian Wang

Topic: “Role of methylation of microRNA in chronic lymphocytic leukemia”

(Since 2011, May – Apr, 2015)


Ph.D. student: Rita Yim

Topic: “Methylation of microRNA in mantle cell lymphoma”

(Since 2011, Dec – Aug, 2014)


Ph.D. student: Bai Yinlei

Topic: “Study of minimal residual disease in multiple myeloma”

(Since 2013, Oct – Sep, 2017)


Ph.D. student: Li Zhenhai

Topic: “Study of methylation of long non-coding RNA in multiple myeloma”

(Since 2013, Oct – Sep, 2017)


Ph.D. student: Zhang Minyue

Topic: “Study of methylation of non-coding RNA in lymphoma”

(Since 2014, Sep – Aug, 2018)


Master of Philosophy student: Ng Ho Yin Atwood

60

Topic: “Methylation of microRNA in acute promyelocytic leukemia”

Year of graduation: 2013

8. Co-supervisor:

Master of Medical Science: Mr Chan Shing

Topic: “Generation and Functional Characterization of Dendritic Cells from

Bone Marrow of Patients with Leukaemia Diseases and Various

Haemato-oncological Conditions”

Year of Graduation: 2002

b) External Examiner:

1. PhD thesis of Dr Chng Wee Joo, National University of Singapore,

Singapore, 2010

2. PhD thesis of Dr Teoh Phaik Ju, National University of Singapore, Singapore,

2014

c) Internal Examiner

1. PhD: - 2012

2. MPhil: Ms Tam Hoy Kam Aegean: “Epigenetic dysregulation of microRNA-9 in

hepatocellular carcinoma” - 2010

3. PhD: Ms Lau Choi Yi: “Characterization and application of MP1 homologues in

Penicillium marneffei” – 2009

4. MPhil: Ms Tse Wan Wai: “A study of genomic DNA methylation in

immortalized human epithelial cell lines” – Aug, 2008

5. MPhil: Mr Chiu Kam Hung: “Genetic Aberrations in chronic lymphocytic

leukemia as prognostic markers” – Aug, 2008

d) Post-doctoral Fellow for Project titled: Epigenetic alterations of microRNAs in

multiple myeloma stem cell

(ii) Undergraduate teaching

Teaching activities include student lectures, tutorials, bed-side teaching, case checking,

evening rounds in addition to being examiners for both preclinical and clinical year

students. About 97-99 hours were spent in teaching every year. (appendix 1 & 2)

Appraisals from students are enclosed (appendix 3) However, the teaching activities

actually dated back to the 1990s when I joined the University Department of Medicine in

1991, and has been continually involved in various forms of teaching ever since then.

(iii) Mentoring of Junior Staff

a) Hong Kong Society of Haematology

07/2007 Experience of Complete Remission and update on ATOM trial in multiple

myeloma, Sheraton Hotel

61

08/2004 Experience of Bortezomib in refractory myeloma in Hong Kong, Sheraton

Hotel

04/2006 Gene Hypermethylation in Haemic Cancers, Annual Scientific Meeting, Hong

Kong Society of Haematology, Convention Centre, Hong Kong

11/2005 Essential thrombocythemia in Hong Kong: Prognostic factors to bleeding,

thrombosis, leukaemia and myelofibrosis, Shanghai-Hong Kong Exchange

lecture, Shanghai, China

04/2005 Thalidomide in the treatment of Myeloma

12/2004 Essential Thrombocythemia: prognostic factors and long-term outcome in

Chinese

02/2004 Nasal NK-cell lymphoma: molecular genetics, clinical outcome and

prognostic factors

10/1995 All-Trans Retinoic Acid in the treatment of Acute Promyelocytic Leukemia -

The Hong Kong Scenario

05/1994 Minimal residual disease in B-lineage ALL

b) Hospital Authority or the HK College of Physicians Lectures

03/2003 Anemia in the Elderly

Master of Medical Sciences, University of Hong Kong

10/2001 Haematological problems in pregnancy

The Hong Kong College of Physicians

08/2000 Update on the management of non-Hodgkin’s lymphoma in Year 2000,

The Hong Kong College of Physicians

07/1998 Myeloproliferative disease and myelodysplastic syndrome

School of Professional and Continuing Education, University of Hong Kong

08/1998 Acute Leukemia

School of Professional and Continuing Education, University of Hong Kong

06/1995 Basic Physician Training Lecture

Leukemia and related disorder, Queen Mary Hospital

02/1995 Application of PCR techniques to Haematology

Hospital Authority Commissioned Training for Scientific Officers and

Technicians, 96/96 COC MLT/MT & SO(M)

c) Invited Continual Medical Education (CME) Lectures

04/2007 Management of fungal infections, Hong Kong Baptist Hospital

07/2005 Thrombocytosis in health and disease, St Teresa’s Hospital

07/2005 Fungal infections in the critically ill patients, St Teresa’s Hospital

01/2005 Fungal infections in neutropenic patients, Hong Kong Baptist Hospital

09/2004 Antifungal treatment: from azoles to candins, Hong Kong Sanatorium

62

03/2001 Pyrexia of Unknown Origin: Cluster grand round, Pamela Youde Nethersole

Eastern Hospital

05/2000 Chronic lymphocytic leukemia: To treat or not to treat, Yan Chai Hospital

04/1999 Lymphoma Meeting, Department of Medicine, Pamella Youde Nethersole

Eastern Hospital

11/1997 Tumor suppressor genes on chromosome 9p, Department of Clinical

Oncology, Prince of Wales Hospital

10/1997 Management of Acute Leukemia, Department of Clinical Oncology, Prince

of Wales Hospital

03/1997 Management of Leukemia, Department of Medicine, Princess Margaret

Hospital

05/1996 Common haematological problems, Department of Medicine, United

Christian Hospital.

06/1996 Management of haematological malignancies, Department of Medicine,

United Christian Hospital

d) Research Meeting, University Department of Medicine

04/2017 Multiple Myeloma: What did we learn from our patients? Queen Mary

Hospital

01/2013 DNA methylation in multiple myeloma, Department of Medicine, Queen

Mary Hospital

09/2008 Multiple Myeloma: A long way to CR, Queen Mary Hospital

06/2000 Research meeting: Department of Medicine, Queen Mary Hospital

03/1999 2nd Biennual Meeting of National Congress of Haematology and Oncology

Meeting, Shanghai

08/1997 Research meeting : Department of Medicine, Queen Mary Hospital

02/1994 Research meeting : Department of Medicine, Queen Mary Hospital

12/1993 Research meeting : Department of Haematology, Royal Free Hospital

e) Grand Rounds, University Department of Medicine, Queen Mary Hospital

06/2016 Cord compression in multiple myeloma

09/2009 Convulsion in an anemic patient (TTP)

09/2007 PUO : Catastrophic anti-phospholipid antibody syndrome

03/2005 Thrombocytosis in health & disease

06/2003 The insidious opportunist (fungal infections in the immunocompromised

patients)

06/2001 Fatal EBV-related T-cell lymphoproliferative disease

12/1999 Pyrexia of Unknown Origin (Splenic tuberculosis & Pulmonary Intravascular

Lymphomatosis)

63

04/1998 A very unusual cause of bone pain (Bone marrow necrosis)

12/1996 A Very Fatal Cause of Pancytopenia (Reactive haemophagocytic syndrome)

06/1995 All-Trans Retinoic Acid in the treatment of Acute Promyelocytic Leukemia

f) Advanced Nursing Lectures

10/2015 Post-registration certificate course in Haematological & Bone Marrow

Transplant Nursing, 2015

11/2012 Post-registration certificate course in Haematological & Bone Marrow

Transplant Nursing (2012/13)

2006-2008 Leukemia, Myeloproliferative disease and Myelodysplastic syndrome,

Diploma in Oncology & palliative care for Heath Care Professionals,

SPACE

Oct, 2008 Multiple myeloma & related disease, the Hong Kong Nurses General

Union

03/2000 & 03/1997 Management of lymphoma, myeloma and myelodysplastic syndrome,

Advanced Nursing, Hong Kong

04/1996 Benign disorder of WBC - Advanced Nursing, Hospital Authority,

Hong Kong

04/1996 Leukemia and myelodysplastic syndrome : Advanced Nursing,

Hospital Authority

64

(G) Administrative Activites

(i) University of Hong Kong

(a) System Coordinator of Haematology-Immunology Block of Year 2 Coordinating

Sub-committee (2008 - 2010)

(b) Member of Faculty Computer Committee (2010 - 2016)

(c) Chief Examiner: Post-Graduate Diploma in Diagnosis and Therapeutics in internal

medicine

(d) Member, Selection board for the Sir Edward Youde Memorial Scholarship (2010 - 2011)

(f) Member, Committee of Management of the Sun Yat Sen Foundation Fund for Academic

Exchanges with China (2010 – 2013)

(ii) Department of Medicine, Queen Mary Hospital

a) Chairman: Intern Committee (2004 – 2007)

b) Department representative to :

1. Infection Control Committee (1996 - 2004)

2. Pathology Subcommittee: Hong Kong West Cluster (2004 – now)

(iii) Professional Body Appointments

a) Director of Training Program, Haematology & Haematological Oncology, the Hong Kong

College of Phsyicians:

b) Council bearer of the Hong Kong Society of Haematology :

Council member (Apr 2007 – Mar 2008), Chairman (2003-2006), Honorary treasurer

(2000-2003), Honorary secretary (1999-2000), Scientific officer (1998-1999)

c) Council member: Hong Kong Cancer Chemotherapy Society (2002-now)

d) Council member: Federation of Medical Societies of Hong Kong (2003-now)

e) Chairman: Education Committee, Federation of Medical Societies of Hong Kong

(2007-2009)

f) Director: Foundation of Federation of Medical Societies of Hong Kong (2005-now)

g) Scientific Officer: Hong Kong Society for the Study of Thalassemia (2005-now)

h) Social Services:

1. Member of Cervical Screening Taskforce, Department of Health, Hong Kong (Mar

2002 - Mar 2008)

2. Honorary Advisor: Hong Kong Adult Blood Cancer Group (May 2004 – March 2014,

April 2016 – March 2018)

3. Honorary Advisor: Hong Kong Bone Marrow Transplantation Patient Group

65

(iv) Hospital Authority Head Office: Executive Partner - 2001-2002

Major projects:

a) Cervical Cancer Screening Program: this project is steered by the Cervical Screening

Taskforce (CSTF) chaired by Miss Margaret Chan, Chief, Department of Health. My

major contribution is to assist the Department of Health (under the supervision of DR

Fung Hong, Director, HAHO) in the set-up of an information system, preparation of the

project definition study for submission to the Legco, exploration and settlement of

privacy issues, implementation of security measures, contact with GP & private hospitals

for opinions, and arrangement of surveys to womens’ focus groups. I contribute to these

diverse array of work by active participation in the Taskforce as members to:

1. Cervical Screening Information System

2. Quality Assurance Subcommittee

3. Recruitement and Education Subcommittee

b) Computerised Clinical Decision Support: CDSS at the point-of care is a major trend

in the development if Health Informatics and is the major added value to the current huge

database available in HA, Hong Kong. While there are many hurdles, both technically

and logistically, an attempt has been made to explore the implementation of

computerised clinical practice guidelines in the current CMS and ePR environment.

Firstly, a detailed literature search has been done and a review of the current available

models of CDSS is identified (summarised in: Electronic Clinical Practice Guideline

(eCPG): Current status and future prospects in Hong Kong by Chim CS et al.) Then we

designed a CDSS for the management of DM was tested in TKO Hospital, which

engaged the current CMS in TKOH and the upcoming territory-wide ePR. This trial is

conducted as a randomized controlled trial and the primary end-point is the adherence to

CPG in both intervention and control arms.

c) Computerised Triage Referral Guidelines in PYNEH: PYNEH is a regional hospital that

handles a huge number of medical referrals from other hospitals, departments, and

private practitioners. On the other hand, due to the limited resources, referrals will be

assigned appointments according to the level of clinical urgency. This is efficiently dealt

with by the use of referral triage CPG, to be executed by designated triage nurses. To

take it a step further, if the Triage CPG can be computerised, then it will not only

facilitate the work of the triage nurse, but also the rolling-out to other hospitals, or even

to the referring ends, i.e. referring doctors may obtain an appointment for the patient

from the far end, and save the patients from travelling to the out-patient department of

PYNEH for appointment. This endeavor is accomplished with Drs Loretta Yam, NT

Cheung, Triage nurse team headed by Civy Leung, and the IT team led by Hudson, Dick

Lam and Shirley.

d) Investigation of complaint lodged by Dr Alan Chang from PWH

66

e) Participation in various IT working groups: MOE working group, Clinical data policy

group, Electronic patient record working group, CDARS team

f) Regular meetings:

1. IT Policy Group

2. CMS Policy Executive Group

3. CMS Steering Group

4. Other meetings: SEM meeting, HCE roundtable Meeting, Medical Policy Group,

Administration Journal Clubs, etc.

67

(H) Knowledge Transfer (i) Public Lectures : University of Hong Kong

a) 2018, January 22: Hong Kong Cancer Fund – Lymphoma Cancer booklet

b) 2012, March 17: Explore the World of Medicine: Public Lecture Series 2012 -

Unravelling the Mystery of Multiple Myeloma and Unexplained Symptoms:

“Breakthroughs in the Treatment of Multiple Myeloma”.

c) 2011, April 18: Explore the World of Medicine: Public Lecture Series 2011 –

Disorders of Ageing: Anemia and Rheumatological Diseases: Anemia in the Elderly,

Hong Kong Central Library, Causeway Bay

d) 2008, May 18: Defeating Leukaemia and Multiple Myeloma, Hong Kong Science

Museum

(ii) Hong Kong Society of Myeloma – Patient gathering

1st Myeloma patient gathering in Oct, 2015: to be reported in Winter Issue of

“Myeloma Today” of the International Myeloma Foundation

..\..\..\..\Hong Kong Society of Myeloma\Patient Group\1st gathering 2015 10

09\Myeloma Today_Winter20152016_KE.pdf

2nd Myeloma patient gathering in Apr, 2016: to be reported in the next issue of

Myeloma Today of the International Myeloma Foundation.

3rd Myeloma patient gathering in Nov, 2016: Clinical Pharmacist, Clinical

Psychologist and Registered Dietitian to share in the meeting

4th Myeloma patient gathering in Sept, 2017: Orthopaedic surgeon & Physiotherapy

Sharing

(iii) Media

a) 3rd, Nov, 2016: TVB 無綫互動新聞台【癌症系列】：多發性骨髓瘤診斷與治療 (上)

&1

b) 44th, Nov 2016: TVB 無綫互動新聞台【癌症系列】：多發性骨髓瘤診斷與治療 (下)

c) Bone Marrow Transplantation: Metro News, 22 Apr 2017

d) Multiple Myeloma: Metro News, 15 Dec 2016

e) 杏林在線: Multiple Myeloma,NOW TV,19 Nov 2015

f) RTHK “精靈一點”, 18Apr 2011

g) Myeloma infiltration of the lung: Apple Daily, 29 Dec 2010

h) Hepatitis B reactivation in Lymphoma: Hong Kong Economic Times, 31 Jul 2010

i) Success of a Staged Approach for Myeloma in Hong Kong: Major newspapers (Apply

Daily, Oriental Daily News, Ming Pao Daily News, Sing Tao Daily, Ta Kung Pao, Hong

Kong Economic Times, Hong Kong Daily News, The Sun, am730, Metropolis Daily), 31

May 2010

68

j) the State Award for Technology Advances 2009: Major newspapers (Wen Wei Po,

Apply Daily, Ta Kung Pao, Ming Pao Daily News Sing, Tao Daily), 12 Feb 2010

k) 全球淋巴瘤關注日: Television Broadcasts Limited"都市閒情" interview,15 Sep 2008

l) Multiple myeloma in Hong Kong & advances in treatment: Press Conference, 26 Oct 2007

m) 標靶治療血癌痊愈率高: Sing Pao, 19 May 2008

n) Pollution a risk factor in blood clots, study finds: South China Morning Post, 14 May 2008

o) Hepatosplenomegaly due to chronic malarial infection: Apple Daily, 29 Sep 2004

p) Thrombocytosis in health and disease: Apple Daily, 12 Apr 2006

q) Invasive fungal infection and anti-fungal therapy: Apple Daily, 11 Jul 2006

r) 全港首宗輸血染菌: Apple Daily, 7 Jan 2008

(iv) Chairperson in International & Local Meetings

a) March 2011: Bridging the Gap, Singapore, 2011

b) March, 2011: Update in Multiple Myeloma Treatment, HK Society of Myeloma

c) March, 2011: 3rd Celgene Asia Pacific Expert Meeting (CAPEM), Hong Kong

d) Dec, 2010: Celgene Southeast Asia American Society Hematology (ASH) Myeloma

Symposium, New Orleans, USA

e) Nov, 2009: Targeted Therapy in Cancer, the Hong Kong International Cancer Congress

f) May, 2009: Advances in Management of Bleeding and Thrombosis: Advances in

Medicine 2009, Department of Medicine & Therapeutics, The Chinese University of

Hong Kong, Hong Kong Convention and Exhibition Centre

g) Oct, 2007: Targeted therapy in cancer: The Federation’s Annual Scientific Meeting of

2007.

h) June, 2006: Stem Cells : From bench to bedside: The Federation’s Annual Scientific

Meeting of 2006.

i) May, 2006: Epigenetics in cancer and the basis of demethylation strategies in MDS:

Professor H Grant Prentice, Emeritus Professor, University College Hospital, London.

Sheraton Hotel, Hong Kong.

j) Sep, 2005: Controversies in frontline therapy in the era of novel agents and role of

transplant in MM: Professor Sundar Jagannath, Chief, Multiple Myeloma Service, &

Chief, Bone Marrow and Blood Stem Cell Transplantation Program. Conrad Hotel, Hong

Kong.

k) July, 2005: How to minimize and manage resistance in treatment of CML? Jorge Cortes,

Chief - CML Section, Department of Leukemia, The University of Texas MD Anderson

Cancer Center

Houston, Texas. Island Shangrila Hotel, Hong Kong

l) June, 2005: The use of bortezomib (Velcade) in the management of multiple myeloma.

Dr Palumbo, Sheraton Hotel, Hong Kong

69

m) March, 2005: Leukemia 2005, Hong Kong Society of Haematology & the Department of

Pathology, University of Hong Kong

n) March, 2005: Annual Scientific Meeting, Hong Kong Society of Haematology

o) March, 2004: Annual Scientific Meeting, Hong Kong Society of Haematology

p) Nov, 2003: Hong Kong Thalassaemia Conference 2003.

q) Nov, 1998: 5th Hong Kong International Cancer Congress - Leukemia and Lymphoma

r) Nov, 1997: 14th Asia Pacific Conference & 4th Hong Kong International Congress of

Cancer - Leukemia & Supportive care sessions

(V) Advisor, Adjudicator & Guest of Honor of the Medicine Annual Quiz of Liberal Studies

Cup on Medicine for secondary schools:

2016 – Liberal Studies Cup on Environmental Protection

2015 – Food Wise Liberal Studies Cup

2012 – Liberal Studies Cup in Medicine

Annex I - Editorial Board Members

Editorial Board Members

1. Carcinogenesis (IF: 5.105) (Jan 2009 - Dec 2011)

2. Journal of Hematology & Oncology (IF: 6.350)(since Mar 2012)

3. Journal of Translational Medicine (IF: 3.786)(since Nov 2008)

4. Bone Marrow Transplantation (IF: 3.874)(since Feb 2009)

5. PLoS ONE (IF: 2.806)(since Jul 2010)

6. Blood Cancer Journal (IF: 6.126)

7. Current Oncology Reports (IF: 2.608)(since Jan 2011)

8. International Journal of Oncology (IF: 3.079)(since Feb 2009)

9. Translational Oncology (since Mar 2010) (IF:3.025)

10. American Journal of Molecular Biology (since Oct 2011)

11. Health (since 2009)(http://www.scirp.org/journal/health) (since Oct 2009)

http://www.scirp.org/journal/EditorialBoard.aspx?JournalID=65

12. The Asia-Pacific Journal of Oncology and Hematology (Jan 2010 - 2011)

13. ISRN Hematology (since Jul 2010) )

14. Scientifica-Immunology (since Feb 2012)

15. Hematology and Leukemia (Herbert Open Access Journals) (since 2012)

16. The Open Clinical Cancer Journal (since Mar 2007)

17. The Open Pathology Journal (since Jan 2008)

18. The Open Surgical Oncology Journal (since Jun 2008)

19. The Hong Kong Medical Diary (since Jan 2008)

20. The Open Translational Medicine Journal (since Jul 2008)

21. The Open Leukemia Journal (since Aug 2008)

22. Journal of Chinese Clinical Medicine (since Nov 2005)

23. Chinese Journal of Current Clinical Medicine《中華現代臨床醫學雜誌》

24. 《白血病·淋巴瘤》雜誌 (since May 2009)

25. Journal of Life Medicine (since Jan 2013)

26. International Journal of Health (since Feb 2013)

27. Transplantation Technology (since Mar 2013)

28. Molecular Biology and Genetic Engineering (since Apr 2013)

29. Modern Chemotherapy (Jul 2013 – Jun 2016)

30. Applied Scientific Reports (since Sep 2013)

31. Case Reports in Oncological Medicine (since Sep 2013)

32. Global Journal of Hematology and Blood Transfusion (since Apr 2014)

33. HSOA Journal of Hematology, Blood Transfusion and Disorders (HBTD) (since Apr 2014)

34. Journal of cancer studies and therapy

35. The Open Access Journal of Science and Technology

36. Austin Biomarkers & Diagnosis


37. Current Advances in Chemistry Research (CACR)

38. Cancer Reports (BioMed Best) (since 2010)

39. Trends in Molecular Biology (Oct 2013 – Sep 2014)

40. Frontiers in Biological Chemistry (Oct 2013 – Sep 2014)

41. International Journal of Advanced Chemistry Research (IJACR) (since Nov 2013)

42. Journal of Cancer Metastasis and Treatment (since Nov 2014)

43. International Journal of Hematology Research (IJHR) (since Nov 2014)

44. International Journal of Cancer Immunology & Immunotherapy (since Nov 2014)

45. World Journal of Clinical Oncology (since Jan 2015)

46. Non-Coding RNA (since Feb 2015)

47. Henry Journal of Hematology & Hemotherapy (since Oct 2015)

48. SRL Oncology & Hematology (since Dec 2015)

49. Gavin Journal of Stem Cell Research and Therapy (since Jan 2016)

50. Gavin Journal of Case Reports (since Mar 2016)

51. JBR Journal of Translational Clinical & Experimental Oncology (JBR-TCEO) (since Mar 2016)

52. Remedy Open Access Journal (since Mar 2016)

53. Clinics in Oncology (since May 2016)

54. Gavin Journal of Blood (since Jul 2016)

55. JBR Journal of Translational Clinical & Experimental Oncology (JBR-TCEO) (since May 2016)

56. Austin Leukemia (since May 2016)

57. The Scientific Pages of Hematology

58. Journal of Clinical Epigenetics (since Jul 2016)

59. Molecular Medicine Open Access (since Sep 2016)

60. Insights in Clinical Pharmacology (since Sep 2016)

61. The Open Access Journal of Science and Technology (since Dec 2016)

62. Annals of Lymphoma (since Jan 2017)

63. Journal of Oncology and Cancer Research (since Jan 2017)

64. Journal of Bioresearch Communication (since Feb 2017)

65. SRL Molecular Biomarkers & Diagnosis (since Feb 2017)

66. Thrombosis & Haemostasis: Research (since Feb 2017)

67. Annals of Transplantation Research (since Feb 2017)

68. SM Hematology & Multiple Myeloma (since Mar 2017)

69. International e-Journal of Cancer Research (since Mar 2017)

70. Cellular & Molecular Medicine Research (since Mar 2017)

71. Cancer Studies (since Apr 2017)

72. Journal of Translational Science and Research (since May 2017)

73. Clinical Cancer Drugs (since Sep2017)

74. MicroRNA (since Oct, 2017): http://benthamscience.com/journals/microrna/

75. Journal of Biochemistry Research (since Nov, 2017)


76. Journal of Dermatopathology (since Nov, 2017)

77. Chinese Cinical Oncology (since Jan 2018)

Documents

Curriculum Vitae of - HKU Scholars Hub: Homehub.hku.hk/.../35/?filename=Dr_CS_Chim_Full_20180206.pdf · edicin ospita ng Ko ng (UK), Glas), F FHKCP & On e, l, ng ACP, , FHKA cology